PRMT5-MTA synergistic inhibitor, pharmaceutical composition thereof and use thereof

By developing a PRMT5-MTA co-synergistic inhibitor, the problem of the limited types of existing inhibitors has been solved, and a treatment option that selectively kills MTAP-deficient tumor cells has been provided, especially for effective treatment of MTAP-deficient cancers.

WO2026233301A1PCT designated stage Publication Date: 2026-11-12SUNSHINE LAKE PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/094852
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-01-16
Filing Date
2026-05-06
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

There are currently limited types of PRMT5-MTA synergistic inhibitors, and no mature drugs are on the market, making it difficult to effectively inhibit cancers associated with MTAP deficiency.

Method used

To develop a PRMT5-MTA co-synergistic inhibitor that selectively kills MTAP-deficient tumor cells by inhibiting the binding of SAM to PRMT5, and to provide a pharmaceutical composition containing this compound for cancer treatment.

Benefits of technology

It achieves selective inhibition of MTAP-deficient tumor cells, providing more cancer treatment options, especially for MTAP-deficient cancers such as ovarian cancer and lung cancer.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026094852-FTAPPB-I100001
    Figure PCTCN2026094852-FTAPPB-I100001
  • Figure PCTCN2026094852-FTAPPB-I100002
    Figure PCTCN2026094852-FTAPPB-I100002
  • Figure PCTCN2026094852-FTAPPB-I100003
    Figure PCTCN2026094852-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention belongs to the field of medicinal chemistry, and relates to a PRMT5-MTA synergistic inhibitor, a pharmaceutical composition thereof, and the use thereof in drugs. Specifically, the present invention relates to compounds of formula (I), or stereoisomers, tautomers, nitrogen oxides, solvates, metabolites, pharmaceutically acceptable salts or prodrugs of the compounds of formula (I). The compounds and the pharmaceutical composition thereof involved in the present invention can be used for preparing drugs for preventing or treating PRMT5-related diseases, and in particular, can be used for preparing drugs for preventing or treating PRMT5-related cancers.
Need to check novelty before this filing date? Find Prior Art

Description

PRMT5-MTA co-collaborative inhibitor, pharmaceutical composition thereof and application INVENTION FIELD

[0001] The present application belongs to the field of medicine, and particularly relates to a kind of PRMT5-MTA co-collaborative inhibitor, pharmaceutical composition thereof and its application in medicine. BACKGROUND

[0002] PRMT5 (Protein Arginine Methyltransferase 5) is an important member of the protein arginine methyltransferase family, which catalyzes the symmetric dimethylation (sDMA) modification of arginine residues, and is involved in processes such as gene transcription regulation, RNA splicing, and DNA damage repair. Experiments have shown that PRMT5 is abnormally highly expressed in various cancers (such as lung cancer, breast cancer, and hematological tumors), and drives tumorigenesis by inhibiting tumor suppressor genes (such as p53 and ST7) or activating pro-cancer pathways (such as Wnt / β-catenin). The MTA (Metastasis-Associated Antigen) family, including MTA1, MTA2 and MTA3, is a core component of the NuRD (Nucleosome Remodeling and Histone Deacetylation) complex, which inhibits target gene transcription through chromatin remodeling and histone deacetylation (HDAC). In normal cells, MTA is broken down by MTAP (methylthioadenosine phosphorylase), but in about 15% of cancers (such as glioma, pancreatic cancer, and mesothelioma), the MTAP gene is deleted, leading to accumulation of MTA. Studies have shown that PRMT5-MTA co-collaborative inhibitors can selectively inhibit PRMT5 function in MTAP-deficient tumors, while having less effect on normal cells, achieving precise treatment.

[0003] Although there are already a number of PRMT5-MTA co-collaborative inhibitors that have been shown to have significant anti-tumor effects in vitro in multiple tumor cell lines (MTAP-deficient), the number of inhibitors is limited, and there are no mature drugs on the market, so there is an urgent need to develop more new PRMT5-MTA co-collaborative inhibitors to prevent and treat MTAP-deficient related cancers, providing more drug options for clinical application. SUMMARY

[0004] The present application provides a PRMT5-MTA co-collaborative inhibitor that can inhibit the binding of SAM to PRMT5, thereby selectively killing MTAP-deficient tumor cells for the treatment of cancer. The present application further provides a pharmaceutical composition comprising such compounds, and the use of such compounds and their pharmaceutical compositions in the preparation of a medicament for preventing or treating cancer.

[0005] In one aspect, the present application provides a compound, which is a compound of Formula (I) or a stereoisomer, a tautomer, an N-oxide, a solvate, a metabolite, a metabolic precursor, a pharmaceutically acceptable salt, or a prodrug of a compound of Formula (I),

[0006] wherein R is

[0007] is a single or double bond; L is C 2-6 alkenylene or C 2-6 alkynylene;

[0008] X1is N or CR X1 , X2is N or CR X2 , X3is N or CR X3 ; X8is N or CR X8 ; R X1 , R X2 , R X3 and R X8 are each independently H, D, -CN, halogen, C 1-6 alkyl, C 1-6 heteroalkyl, C 1-6 hydroxyalkyl, or C 1-6 haloalkyl;

[0009] X4is N, C or CR X4 , X5is N, C or CR X5 , X6is N, C or CR X6 , X7is N, C or CR X7 ; R X4 , R X5 , R X6 and R X7 are each independently H, D, -CN, halogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-6 haloalkyl;

[0010] W is O, S, NR W1 or C(R W2 )2; R W1 on N is H, D, C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-6 haloalkyl; 2 R W2 on C are the same or different, each R W2 is independently H, D, -CN, halogen, C 1-6 alkyl, C 1-6 hydroxyalkyl, or C 1-6 haloalkyl, or 2 RW2 Together with the carbon atoms they are attached to, they form =O or =S;

[0011] Ring A and ring B are each independently C 3-6 Carbocyclic rings, 3-10 membered heterocyclic rings, 5-10 membered heteroaromatic rings, or C 6-10 Aromatic rings;

[0012] R 1 H, D, halogen, -CN, -NR a R b C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkyl groups;

[0013] Each R 2 Each is independently D, halogen, -CN, -NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms they are attached to, they form =O or =S;

[0014] Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic groups, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl; or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S;

[0015] Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-6 Alkyl or C1-6 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6 Carbon rings or 3-10 membered heterocyclic rings;

[0016] Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl groups;

[0017] R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10 Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 4 Replaced;

[0018] Each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10 Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 5 The two R atoms that are replaced or attached to the same carbon atom are replaced. 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ;

[0019] Each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-10 membered heterocyclic groups; wherein, the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 The cycloalkyl or 3-10 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ;

[0020] Each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Heteroalkyl or C 1-6 Halogenated alkyl groups;

[0021] Each R p R q R s Rt Independent of H, D, halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl or C 1-6 Haloalkyl; the values ​​of S1 and S2 are positive integers, and the sum of S1 and S2 is 2, 3 or 4;

[0022] m can be 0, 1, 2, 3, 4, 5, or 6.

[0023] In some implementations, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-4 Alkyl, C 1-4 Heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 1-4 Halogenated alkyl or C 1-4 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Halogenated alkyl or C 1-4 Deuterated alkyl; or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S;

[0024] Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-4 Alkyl or C 1-4 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6 Carbon rings or 3-6 membered heterocycles;

[0025] Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl groups.

[0026] In some implementation schemes, R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 4 Replaced;

[0027] Each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, 5-6 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6-membered heterocyclic, 5-6-membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 5 The replaced; or two R atoms attached to the same carbon atom 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ;

[0028] Each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C3-6 Cycloalkyl or 3-6 membered heterocyclic groups; wherein, the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 The cycloalkyl or 3-6 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ;

[0029] Each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups;

[0030] Each R p R q R s R t Independent of H, D, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups.

[0031] In some implementations, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups;

[0032] X4 represents N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups;

[0033] W represents O, S, and NR. W1 or C(R) W2 )2; R on N W1 For H, D, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Haloalkyl; 2 Rs on C W2 Whether they are the same or different, each R W2 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl group, or two R groups on C W2 Together with the carbon atoms they are attached to, they form =O or =S.

[0034] In some implementations, ring A and ring B are each independently designated as C. 3-6 Carbon rings, 3-6 membered heterocycles, 5-6 membered heteroaromatic rings, or benzene rings;

[0035] R 1 H, D, halogen, -CN, -NR a R b C 1-4 Alkyl, C 1-4 Alkoxy or C 1-4 Halogenated alkyl groups;

[0036] R 2 Each is independently D, halogen, -CN, -NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl or C 1-4 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms they are attached to, they form =O or =S.

[0037] In some implementations, L is C 2-4imide or C 2-4 Alynyl group.

[0038] In some embodiments, the compound of the present invention is a compound of formula (II-1) or (II-2), or a stereoisomer, geometric isomer, tautomer, nitride, hydrate, solvate, metabolite, metabolic precursor, pharmaceutically acceptable salt, or prodrug of a compound of formula (II-1) or (II-2).

[0039] Among them, L, R, R 3 R Y1a Each has the definition described in this invention.

[0040] In some implementations, R is selected from any of the following structures:

[0041] Among them, R X1 R X2 R X3 R X8 R 1 R 2 Each of and m has the definition described in this invention.

[0042] On the other hand, the present invention provides a pharmaceutical composition comprising the compound described herein or a stereoisomer, tautomer, nitride, solvate, metabolite, pharmaceutically acceptable salt, or prodrug; optionally, it further comprises a pharmaceutically acceptable carrier.

[0043] On the other hand, the present invention provides the use of the compounds or pharmaceutical compositions described herein in the preparation of a medicament, wherein the medicament is used to protect against, treat, cure or alleviate cancer in a patient.

[0044] In some implementations, the cancer is MTAP deficiency-related cancer; optionally, the MTAP deficiency-related cancer is ovarian cancer, lung cancer, lymphoma, glioblastoma, colon cancer, melanoma, gastric cancer, bile duct cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0045] On the other hand, the present invention provides compounds or pharmaceutical compositions described herein for the prevention, treatment or treatment of cancer.

[0046] On the other hand, the present invention provides a method for preventing, treating or treating cancer, comprising administering a patient a therapeutically effective amount of the compound or pharmaceutical composition described herein.

[0047] On the other hand, the present invention relates to methods for the preparation, separation and purification of compounds represented by formula (I), (II-1) or (II-2).

[0048] Unless otherwise indicated, all stereoisomers, tautomers, nitrides, hydrates, solvates, metabolites, salts, and pharmaceutically acceptable prodrugs of the compounds of this invention are within the scope of this invention.

[0049] Specifically, the salt is a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically or toxicologically suitable in relation to the other components of the formulation and the mammal intended for treatment.

[0050] The salts of the compounds of the present invention also include salts of intermediates used for the preparation or purification of compounds of formula (I), (II-1) or (II-2) or salts of enantiomers isolated from compounds of formula (I), (II-1) or (II-2), but are not necessarily pharmaceutically acceptable salts.

[0051] The foregoing description only outlines certain aspects of the invention, but is not limited to these aspects. These and other aspects will be described in more detail below.

[0052] Detailed specifications

[0053] Definitions and general terms

[0054] Certain embodiments of the invention will now be described in detail, examples of which are illustrated by the accompanying structural and chemical formulas. The invention is intended to encompass all alternatives, modifications, and equivalents, all of which are included within its scope. Those skilled in the art will recognize that many similar or equivalent methods and materials can be used to practice the invention. The invention is by no means limited to the methods and materials described herein. In the event that one or more of the incorporated documents, patents, and similar materials differ from or contradict this application (including, but not limited to, defined terminology, application of terminology, described techniques, etc.), this application shall prevail.

[0055] It should be further appreciated that certain features of the invention, for clarity, have been described in multiple independent embodiments, but may also be provided in combination in a single embodiment. Conversely, various features of the invention, for brevity, have been described in a single embodiment, but may also be provided individually or in any suitable sub-combination.

[0056] Unless otherwise stated, all technical terms used in this invention have the same meaning as commonly understood by one of ordinary skill in the art. All patents and publications related to this invention are incorporated herein by reference in their entirety.

[0057] Unless otherwise stated or there is a clear conflict in the context, the articles “a,” “an,” and “described” as used herein are intended to include “at least one” or “one or more.” Therefore, these articles as used herein refer to articles for one or more (i.e., at least one) objects. For example, “a component” refers to one or more components, meaning that more than one component may be considered for use or adoption in the implementation of the described embodiments.

[0058] As used in this invention, the term "patient" refers to a person (including adults and children) or other animal. In some embodiments, "patient" refers to a person.

[0059] The term "comprising" is an open-ended expression, meaning it includes the contents specified in this invention, but does not exclude other aspects.

[0060] "Stereoisomers" refer to compounds that have the same chemical structure but differ in the spatial arrangement of their atoms or groups. Stereoisomers include enantiomers, diastereomers, conformational isomers (rotational isomers), geometrical isomers (cis / trans) isomers, trans-blocking isomers, and so on. Unless otherwise stated, all stereoisomers or mixtures of stereoisomers of the structural formulas described in this invention are within the scope of this invention. Furthermore, unless otherwise stated, the structural formulas of the compounds described in this invention include enriched isotopes of one or more different atoms.

[0061] The stereochemical definitions and rules used in this invention generally follow those of S.P. Parker, Ed., McGraw-Hill Dictionary of Chemical Terms (1984), McGraw-Hill Book Company, New York; and Eliel, E. and Wilen, S., “Stereochemistry of Organic Compounds,” John Wiley & Sons, Inc., New York, 1994.

[0062] Any asymmetric atom (e.g., carbon, etc.) in the compounds disclosed in this invention can exist in a racemic or enantiomerically enriched form, such as in (R)-, (S)-, or (R,S)- configurations. In some embodiments, each asymmetric atom has at least 50% enantiomeric excess, at least 60% enantiomeric excess, at least 70% enantiomeric excess, at least 80% enantiomeric excess, at least 90% enantiomeric excess, at least 95% enantiomeric excess, or at least 99% enantiomeric excess in the (R)- or (S)- configuration.

[0063] Depending on the choice of starting materials and methods, the compounds of this invention can exist as one or a mixture of possible isomers, such as racemic mixtures and mixtures of non-corresponding isomers (depending on the number of asymmetric carbon atoms). Optically active (R)- or (S)- isomers can be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques. If the compound contains a double bond, the substituents may be E or Z configurations; if the compound contains a disubstituted cycloalkyl group, the cycloalkyl substituents may be cis or trans configurations.

[0064] Any mixture of stereoisomers obtained can be separated into pure or substantially pure geometric isomers, enantiomers, and diastereomers based on differences in the physicochemical properties of the components, for example, by chromatography and / or fractional crystallization.

[0065] The terms "tautomer" or "tautomer form" refer to structural isomers with different energies that can interconvert through a low energy barrier. If tautomerism is possible (e.g., in solution), chemical equilibrium can be achieved in the tautomer. For example, proton tautomers (also called prototropic tautomers) involve interconversions via proton migration, such as keto-enol isomerization and imine-enamine isomerization. Valence tautomers involve interconversions via the rearrangement of some bonding electrons. A specific example of a keto-enol tautomer is the interconversion between pentane-2,4-dione and 4-hydroxypent-3-en-2-one. Another example of tautomerism is phenol-keto tautomerism. A specific example of a phenol-keto tautomer is the interconversion between pyridine-4-ol and pyridine-4(1H)-keto. Unless otherwise stated, all tautomer forms of the compounds of this invention are within the scope of this invention.

[0066] The term "optional" or "optionally" means that an event or situation described below may, but is not guaranteed to, occur, and the description includes both the possibility that the event or situation occurs and the possibility that it does not occur. For example, "optional key" means that the key may or may not be present, and the description includes single, double, or triple keys.

[0067] The term "substituted" indicates that one or more hydrogen atoms in the given structure are substituted by a specific substituent. As described in this invention, the compounds of this invention may optionally be substituted by one or more substituents, such as the general formula compounds above, or as in the specific examples, subclasses, and classes of compounds included in this invention. The term "optionally substituted" may be used interchangeably with the term "unsubstituted or substituted," meaning that the structure is unsubstituted or substituted by one or more substituents as described in this invention.

[0068] Unless otherwise indicated, an optional substituent group may be substituted at each substituted position of the group. When more than one position in the given structural formula can be substituted by one or more substituents selected from a particular group, the substituents may be substituted at each position in the same or different manner.

[0069] The term "unsubstituted" means that the specified group does not have substituents.

[0070] Additionally, it should be noted that, unless otherwise explicitly stated, the descriptive terms “each…independently is”, “…each independently is”, and “…independently is” used in this invention are interchangeable and should be interpreted broadly. They can mean that the specific options expressed by the same symbols in different groups do not affect each other, or that the specific options expressed by the same symbols in the same group do not affect each other.

[0071] In various parts of this specification, the substituents of the disclosed compounds are disclosed according to the type or range of groups. In particular, the invention includes every independent sub-combination of the members of these types and ranges. For example, the term "C1-C6 alkyl" specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl, and C6 alkyl groups.

[0072] In various parts of this invention, linking substituents are described. When the structure clearly requires a linking group, the Markush variables listed for that group should be understood as linking groups. For example, if the structure requires a linking group and the Markush group definition for that variable lists "alkyl," "alken," "alkynyl," or "aryl," then it should be understood that "alkyl," "alken," "alkynyl," or "aryl" represents a linked alkylene group, alkenene group, alkynyl group, or aryl group, respectively.

[0073] As used in this invention, the term "alkyl" refers to a saturated straight-chain or branched monovalent hydrocarbon group containing 1 to 20 carbon atoms, wherein the alkyl group may optionally be substituted by one or more substituents described in this invention. In some embodiments, the alkyl group contains 1 to 12 carbon atoms, denoted as C1. 1-12Alkyl group; in other embodiments, the alkyl group contains 1-6 carbon atoms, denoted as C1. 1-6 Alkyl group; in some further embodiments, the alkyl group contains 1-4 carbon atoms, denoted as C1. 1-4 Alkyl group; in some embodiments, the alkyl group contains 1-3 carbon atoms, denoted as C1. 1-3 Alkyl groups. Examples of alkyl groups include, but are not limited to, methyl (Me, -CH3), ethyl (Et, -CH2CH3), n-propyl (n-Pr, -CH2CH2CH3), isopropyl (i-Pr, -CH(CH3)2), n-butyl (n-Bu, -CH2CH2CH2CH3), isobutyl (i-Bu, -CH2CH(CH3)2), sec-butyl (s-Bu, -CH(CH3)CH2CH3), tert-butyl (t-B) u、-C(CH3)3), n-pentyl(-CH2CH2CH2CH2CH3), 2-pentyl(-CH(CH3)CH2CH2CH3), 3-pentyl(-CH(CH2CH3)2), 2-methyl-2-butyl(-C(CH3)2CH2CH3), 3-methyl-2-butyl(-CH(CH3)CH(CH3)2), 3-methyl-1-butyl(-CH2CH2CH(CH3)2), 2-methyl-1 -Butyl (-CH2CH(CH3)CH2CH3), n-hexyl (-CH2CH2CH2CH2CH2CH3), 2-hexyl (-CH(CH3)CH2CH2CH2CH3), 3-hexyl (-CH(CH2CH3)(CH2CH2CH3)), 2-methyl-2-pentyl (-C(CH3)2CH2CH2CH3), 3-methyl-2-pentyl (-CH(CH3)CH(CH3)CH2CH3) ), 4-methyl-2-pentyl (-CH(CH3)CH2CH(CH3)2), 3-methyl-3-pentyl (-C(CH3)(CH2CH3)2), 2-methyl-3-pentyl (-CH(CH2CH3)CH(CH3)2), 2,3-dimethyl-2-butyl (-C(CH3)2CH(CH3)2), 3,3-dimethyl-2-butyl (-CH(CH3)C(CH3)3), n-heptyl, n-octyl, etc.

[0074] The term "hydroxyalkyl" refers to an alkyl group substituted with one or more hydroxyl groups, wherein the alkyl group and the hydroxyl group have the definitions as described in this invention. In some embodiments, hydroxyalkyl refers to an alkyl group substituted with 1, 2, 3, or 4 hydroxyl groups. In some embodiments, hydroxyalkyl refers to an alkyl group substituted with one or two hydroxyl groups. In some embodiments, hydroxyalkyl refers to a C14-C ... 1-6 Hydroxyalkyl, i.e., C 1-6 Alkyl groups are substituted with one or more hydroxyl groups, preferably C 1-6Hydroxyalkyl means a C that has been substituted with a hydroxyl group. 1-6 Alkyl. In some embodiments, hydroxyalkyl indicates C10. 1-4 Hydroxyalkyl. In some embodiments, hydroxyalkyl means C 1-3 Hydroxyalkyl groups. Examples of hydroxyalkyl groups include, but are not limited to, -CH2OH, -CH2CH2CH2CH2OH, -CH2CH2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, etc.

[0075] The term "haloalkyl" indicates that an alkyl group is replaced by one or more halogen atoms, wherein the alkyl group and the halogen atom have the definitions described herein. In some embodiments, the haloalkyl group is C10. 1-6 Haloalkyl, indicating C 1-6 The alkyl group is replaced by one or more halogen atoms; in other embodiments, the haloalkyl group is C10. 1-4 Haloalkyl, indicating C 1-4 The alkyl group is replaced by one or more halogen atoms; in other embodiments, the haloalkyl group is C10. 1-3 Haloalkyl, indicating C 1-3 The alkyl group is replaced by one or more halogen atoms. Examples of such groups include, but are not limited to, monofluoromethyl, difluoromethyl, trifluoromethyl, 1-fluoroethyl, 2-fluoroethyl, 1,2-difluoroethyl, 1,1-difluoroethyl, 2,2-difluoroethyl, monochloromethyl, dichloromethyl, trichloromethyl, 2-chloroethyl, 1-chloroethyl, 1,2-dichloroethyl, 1,1-dichloroethyl, 2,2-dichloroethyl, 1,1-dibromoethyl, and so on.

[0076] The term "alkylene" refers to a saturated divalent hydrocarbon group obtained by removing two hydrogen atoms from a saturated straight-chain or branched hydrocarbon group. Unless otherwise specified, the alkylene group contains 1-12 carbon atoms. In some embodiments, the alkylene group contains 1-6 carbon atoms; in others, it contains 1-4 carbon atoms; in still others, it contains 1-3 carbon atoms; and in still still others, it contains 1-2 carbon atoms. Examples of such groups include methylene (-CH2-), ethylene (-CH2CH2-), isopropylene (-CH(CH3)CH2-), and so on.

[0077] The term "heteroalkyl" refers to an alkyl group whose main chain carbon atoms have one or more skeletal chain atoms independently selected from heteroatoms other than carbon, such as oxygen, nitrogen, sulfur, phosphorus, or combinations thereof. Connection to the rest of the molecule can be made via heteroatoms or carbon atoms in the heteroalkyl chain. In some embodiments, the heteroalkyl group consists of 1-6 carbon atoms, denoted as C1. 1-6The heteroalkyl group, in this example comprising 1-6 carbon atoms, may have one or more heteroatoms; in other embodiments, the heteroalkyl group consists of 1-4 carbon atoms, denoted as C1. 1-4 The heteroalkyl group, in this example comprising 1-4 carbon atoms, may have one or more heteroatoms; in still other embodiments, the heteroalkyl group consists of 1-2 carbon atoms, denoted as C1. 1-2 Heteroalkyl groups, in this example comprising 1-2 carbon atoms, may have one or more heteroatoms. Examples of heteroalkyl groups include, but are not limited to, C3 heteroalkyl groups: -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, C4 heteroalkyl groups: -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, etc.

[0078] The term "alkenyl" refers to a straight-chain or branched monovalent hydrocarbon group containing 2-12 carbon atoms, with at least one unsaturated site, i.e., one carbon-carbon sp. 2 The double bond, wherein the alkenyl group may optionally be substituted by one or more substituents described in this invention, including the orientation of "cis" and "tans", or the orientation of "E" and "Z". In one embodiment, the alkenyl group comprises 2-8 carbon atoms; in another embodiment, the alkenyl group comprises 2-6 carbon atoms; in yet another embodiment, the alkenyl group comprises 2-4 carbon atoms. Examples of alkenyl groups include, but are not limited to, vinyl (-CH=CH2), allyl (-CH2CH=CH2), etc.

[0079] The term "alkenyl" refers to a divalent alkenyl group obtained by removing two hydrogen atoms from a straight-chain or branched alkenyl group.

[0080] The term "alkynyl" refers to a straight-chain or branched monovalent hydrocarbon group containing 2-12 carbon atoms, wherein there is at least one unsaturated site, i.e., one carbon-carbon sp triple bond, wherein the alkynyl group may optionally be substituted by one or more substituents described in this invention. In some embodiments, the alkynyl group contains 2-8 carbon atoms; in other embodiments, the alkynyl group contains 2-6 carbon atoms; and in still other embodiments, the alkynyl group contains 2-4 carbon atoms. Examples of alkynyl groups include, but are not limited to, ethynyl (-C≡CH), propynyl (-CH2C≡CH), 1-propynyl (-C≡C-CH3), etc.

[0081] The term "ethynyl" refers to a divalent ethynyl group obtained by removing two hydrogen atoms from a straight-chain or branched ethynyl group.

[0082] The term "alkoxy group" indicates that an alkyl group is attached to the remainder of the molecule by an oxygen atom, wherein the alkyl group has the meaning as described in this invention. Unless otherwise specified, the alkoxy group contains 1-12 carbon atoms. In some embodiments, the alkoxy group contains 1-6 carbon atoms; in other embodiments, the alkoxy group contains 1-4 carbon atoms; and in still other embodiments, the alkoxy group contains 1-3 carbon atoms. The alkoxy group may optionally be substituted by one or more substituents described in this invention. Examples of alkoxy groups include, but are not limited to, methoxy (MeO, -OCH3), ethoxy (EtO, -OCH2CH3), 1-propoxy (n-PrO, n-propoxy, -OCH2CH2CH3), 2-propoxy (i-PrO, i-propoxy, -OCH(CH3)2), 1-butoxy (n-BuO, n-butoxy, -OCH2CH2CH2CH3), 2-methyl-l-propoxy (i-BuO, i-butoxy, -OCH2CH(CH3)2), 2-butoxy (s-BuO, s-butoxy, -OCH(CH3)CH2CH3), 2-methyl-2- Propoxy (t-BuO, t-butoxy, -OC(CH3)3), 1-pentoxy (n-pentoxy, -OCH2CH2CH2CH2CH3), 2-pentoxy (-OCH(CH3)CH2CH2CH3), 3-pentoxy (-OCH(CH2CH3)2), 2-methyl-2-butoxy (-OC(CH3)2CH2CH3), 3-methyl-2-butoxy (-OCH(CH3)CH(CH3)2), 3-methyl-l-butoxy (-OCH2CH2CH(CH3)2), 2-methyl-l-butoxy (-OCH2CH(CH3)CH2CH3), etc.

[0083] The term "carbocyclic" or "carbocyclic" refers to a monovalent or polyvalent, non-aromatic, saturated or partially unsaturated monocyclic, bicyclic, or tricyclic system containing 3 to 12 carbon atoms. Carbocyclic groups include spirobicyclic, fused, and bridged carbocyclic groups. Suitable carbocyclic groups include, but are not limited to, cycloalkyl, cycloalkenyl, and cycloynyl groups. Further examples of carbocyclic groups include cyclopropyl, cyclobutyl, cyclopentyl, 1-cyclopentyl-1-enyl, 1-cyclopentyl-2-enyl, 1-cyclopentyl-3-enyl, cyclohexyl, 1-cyclohexyl-1-enyl, 1-cyclohexyl-2-enyl, 1-cyclohexyl-3-enyl, cyclohexadienyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cycloundecyl, cyclododecyl, and so on.

[0084] The term "cycloalkyl" refers to a monovalent or polyvalent non-aromatic monocyclic, bicyclic, or tricyclic system containing 3-12 carbon atoms, wherein the -CH2- group in the carbon ring may optionally be replaced by -C(=O)- (or -(CO)-). In some embodiments, the cycloalkyl group comprises 3-12 carbon atoms, i.e., C 3-10 Cycloalkyl; in other embodiments, the cycloalkyl group comprises 3-8 carbon atoms, i.e., C646. 3-8 Cycloalkyl; in some further embodiments, the cycloalkyl group comprises 3-6 carbon atoms, i.e., C64-C ... 3-6 Cycloalkyl; in another embodiment, the cycloalkyl group comprises 3-5 cyclic carbon atoms, i.e., C14-C54. 3-5 Cycloalkyl groups. Examples of cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, etc. Examples of substitution of the -CH2- group in the carbide ring by -C(=O)- include, but are not limited to, cyclopentanone, cyclobutanone, etc. The cycloalkyl groups may optionally be substituted by one or more substituents described in this invention.

[0085] The terms "heterocycle" and "heterocyclic group" are used interchangeably herein to refer to a monovalent or polyvalent monocyclic, bicyclic, or tricyclic system comprising 3-14 ring atoms, wherein one or more atoms on the ring are independently replaced by heteroatoms, which have the meaning as described herein. The ring may be fully saturated or contain one or more degrees of unsaturation, but no aromatic rings are permitted. When a heterocycle is attached to other parts of a molecule via a linking site, the heterocycle is represented as a monovalent heterocyclic group. Unless otherwise stated, the heterocyclic group may be a carbonyl or heteroatomyl group, and the -CH2- group may optionally be replaced by -C(=O)-; the nitrogen atom of the ring may optionally be oxidized to an N-oxide; and the sulfur atom of the ring may optionally be oxidized to an S-oxide (such as a group of SO, SO2). In some embodiments, the heterocycle or heterocyclic group consists of 3-10 atoms and is represented as a 3-10 membered heterocycle or a 3-10 membered heterocyclic group; in other embodiments, the heterocycle or heterocyclic group consists of 3-9 atoms and is represented as a 3-9 membered heterocycle or a 3-9 membered heterocyclic group; in still other embodiments, the heterocycle or heterocyclic group consists of 5-9 atoms and is represented as a 5-9 membered heterocycle or a 5-9 membered heterocyclic group; in still other embodiments, the heterocycle or heterocyclic group consists of 3-6 atoms and is represented as a 3-6 membered heterocycle or a 3-6 membered heterocyclic group; in still other embodiments, the heterocycle or heterocyclic group consists of 5-6 atoms and is represented as a 5-6 membered heterocycle or a 5-6 membered heterocyclic group. The heterocyclic group may optionally be substituted by one or more substituents described in this invention. Examples of heterocyclic groups include, but are not limited to, ethylene oxide, azirrobutyl, oxacyclobutyl, thioheterobutyl, pyrrolyl, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxane, dithiaalkyl, thiaalkyl, homopiperazine, homopiperidinyl, oxacycloheptyl, thioheptanyl, oxacycloheptyl, oxacyclobutyl... 2-diaza Base, sulfur nitrogen Examples of heterocyclic groups where the -CH2- group is replaced by -C(=O)- include, but are not limited to, 2-oxopyrrolyl, oxo-1,3-thiazolyl, 2-piperidinone, 3,5-dioxopyridine, pyrimidinedionyl, etc. Examples of heterocyclic groups where the sulfur atom is oxidized include, but are not limited to, sulfolane, thiomorpholinyl 1,1-dioxide, etc.

[0086] The term "aryl" may be used interchangeably with the term "aromatic ring" to refer to a monocyclic, bicyclic, or tricyclic carbocyclic system containing 6-14, 6-12, or 6-10 ring atoms, wherein at least one ring system is aromatic, and each ring system comprises a ring of 3-7 atoms with one or more attachment sites connected to the remainder of the molecule. In some embodiments, the aryl group contains 6-12 ring atoms, denoted as C 6-12 Aryl or 6-12-membered aryl. In some embodiments, the aryl group contains 6-10 ring atoms, denoted as C. 6-10 Aryl or 6-10-membered aryl groups. Examples of aryl groups may include phenyl, naphthyl, 1,2,3,4-tetrahydronaphthyl, and anthraceneyl. The aryl group may optionally be substituted by one or more substituents described in this invention.

[0087] The term "heteroaryl" may be used interchangeably with the terms "heteroaromatic ring" or "heteroaromatic compound" to refer to a monovalent or polyvalent monocyclic, bicyclic, or tricyclic system containing 5-14, 5-12, 5-10, or 5-6 ring atoms, wherein at least one ring is aromatic and at least one ring contains one or more heteroatoms. The heteroaryl group is typically, but not necessarily, linked to the parent molecule via its aromatic ring. Unless otherwise stated, the heteroaryl group can be linked to the remainder of the molecule (e.g., the main structure in the general formula) at any reasonable site (which can be C or N). When a -CH2- group is present in the heteroaryl group, the -CH2- group may optionally be replaced by -C(=O)-; the nitrogen atom of the ring may optionally be oxidized to an N-oxide; and the sulfur atom of the ring may optionally be oxidized to an S-oxide (such as a group of SO, SO2). The heteroaryl group may optionally be substituted by one or more substituents described in this invention. In some embodiments, the heteroaryl group is a heteroaryl group containing 5-12 ring atoms, denoted as a 5-12-membered heteroaryl; in other embodiments, the heteroaryl group is a heteroaryl group containing 5-10 ring atoms, denoted as a 5-10-membered heteroaryl; in still other embodiments, the heteroaryl group is a heteroaryl group containing 5-6 ring atoms, denoted as a 5-6-membered heteroaryl. The heteroaryl group may optionally be substituted by one or more substituents described in this invention.Examples of heteroaryl groups include, but are not limited to, 2-furanyl, 3-furanyl, N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, N-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-pyrimidinyl, 4-pyrimidinyl, 2-pyrimidinyl, 4-pyrimidinyl. 5-pyrimidinyl, pyridazinyl (e.g., 3-pyridazinyl), 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, tetrazolyl (e.g., 5-tetrazolyl), triazolyl (e.g., 2-triazolyl and 5-triazolyl), 2-thienyl, 3-thienyl, pyrazolyl (e.g., 2-pyrazolyl), isothiazolyl, 1,2,3-oxadiazolyl, 1,2,5-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-triazolyl 1,2,3-Thiodiazolyl, 1,3,4-Thiodiazolyl, 1,2,5-Thiodiazolyl, pyrazinyl, 1,3,5-triazinyl; also including, but not limited to, the following bicyclic compounds: benzimidazolyl, benzofuranyl, benzothiopheneyl, indoleyl (e.g., 2-indoleyl), purineyl, quinolinyl (e.g., 2-quinolinyl, 3-quinolinyl, 4-quinolinyl), isoquinolinyl (e.g., 1-isoquinolinyl) (e.g., 3-isoquinolinyl or 4-isoquinolinyl), imidazo[1,2-a]pyridyl, pyrazolo[1,5-a]pyridyl, pyrazolo[1,5-a]pyrimidinyl, imidazo[1,2-b]pyridazinyl, [1,2,4]triazolo[4,3-b]pyridazinyl, [1,2,4]triazolo[1,5-a]pyrimidinyl, [1,2,4]triazolo[1,5-a]pyridyl, etc.

[0088] The term "bicyclic or tricyclic" includes fused rings, bridged rings, and spirocyclic rings. The bicyclic or tricyclic ring may optionally be substituted with one or more substituents described in this invention. Examples of such substituents include, but are not limited to, bicyclic [2.2.1]heptyl, 2-methyl-diazabicyclic [2.2.1]heptyl, etc.

[0089] The terms “fused ring,” “fused ring,” and “fused ring group” are used interchangeably here to refer to a saturated or unsaturated ring system formed by two or more cyclic structures sharing two adjacent ring atoms, which may contain independent or conjugated unsaturated states. Examples of fused ring groups include, but are not limited to, 2,3,3a,4,7,7a-hexahydro-1H-indene, fused bicyclo[3.3.0]octane, fused bicyclo[3.1.0]hexane, 1,2,3,4,4a,5,8,8a-octahydronaphthalene, 3-aza-fused[3.1.0]hexane, 3-aza-bicyclo[3.3.0]octane, hexahydro-furan[3,4-c]pyrrole, hexahydro-thiophene[3,4-c]pyrrole, 3,4,5,6-tetrahydro-cyclopentane[c]thiophene, etc.

[0090] The terms "bridged ring" and "bridged ring group" are used interchangeably herein to refer to a saturated or unsaturated ring system formed by two or more cyclic structures sharing two non-directly connected ring atoms. Examples of such systems include, but are not limited to, bicyclic [2.2.1]heptyl, 2-oxo-5-azabicyclic [2.2.1]heptyl, 2-thio-5-azabicyclic [2.2.1]heptyl, 2-oxo-5-azabicyclic [2.2.1]heptyl, 2,5-diazabicyclic [2.2.1]heptyl, 2-methyl-2,5-diazabicyclic [2.2.1]heptyl, etc. The bridged ring group may optionally be substituted by one or more substituents described in this invention.

[0091] The terms "spirocyclic" and "spirocyclic group" are used interchangeably here to refer to a saturated or unsaturated ring system formed by two or more ring structures sharing a single ring atom. Each ring in a spirobicyclo group can be a carbocyclic or heterocyclic group, and examples include, but are not limited to, 1,4-dioxo-8-azaspiro[4,5]decane-8-yl, 2-oxo-8-azaspiro[4,5]decane-8-yl, 2,8-diazaspiro[4,5]decane-8-yl, 2,7-diazaspiro[4.4]nonane-2-yl, 7-oxo-2-azaspiro[4.5]decane-2-yl, 4-azaspiro[2.4]heptane-5-yl, 4-oxaspiro[2.4]heptane-5-yl, 5-azaspiro[2.4]heptane-5-yl, spiro[2.4]heptyl, spiro[4.4]nonyl, 7-hydroxy-5-azaspiro[2.4]heptane-5-yl, spiro[2.4]heptyl, spiro[4.4]nonyl, etc. The spirocyclic group may optionally be replaced by one or more substituents described in this invention.

[0092] The term "unsaturated" as used in this invention means that the group contains one or more degrees of unsaturation.

[0093] The term "heteroatom" refers to O, S, N, P, and Si, including any oxidation state of N, S, and P; primary, secondary, tertiary amines, and quaternary ammonium salts; or forms in which the hydrogen atom on the nitrogen atom in the heterocycle is substituted, for example, N (like N in 3,4-dihydro-2H-pyrrole), NH (like NH in pyrroleyl), or NR (like NR in N-substituted pyrroleyl).

[0094] The term "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br), or iodine (I).

[0095] The term "hydroxyl" is used alone or in combination with other terms (such as hydroxyalkyl) and signifies -OH.

[0096] The term "composed of jk atoms" or "jk element" indicates that the cyclic group is composed of jk ring atoms, which include carbon atoms and / or heteroatoms such as O, N, S, P, etc.; j and k are each independently any non-zero natural number, and k > j; "jk" includes j, k, and any natural number between them. For example, "composed of 3-8 atoms" or "3-8 element", "composed of 3-6 atoms" or "3-6 element", "composed of 5-10 atoms" or "5-10 element", or "composed of 5-6 atoms" or "5-6 element" indicates that the cyclic group is composed of 3-8 (i.e., 3, 4, 5, 6, 7 or 8), 3-6 (i.e., 3, 4, 5 or 6), 5-10 (i.e., 5, 6, 7, 8, 9 or 10), or 5-6 (i.e., 5 or 6) ring atoms, which include carbon atoms and / or heteroatoms such as O, N, S, P, etc.

[0097] As described in this invention, the substituent (R) y ) f A ring system formed by a single bond attached to a central ring represents f substituents R. y It can be substituted at any replaceable or reasonable position on the ring. For example, equation a represents that ring G can be replaced by f R. y Replacement, when f is greater than 1, each R y They can be independently selected from the same or different substituents.

[0098] As described in this invention, the substituent R y A ring system formed by a single bond connecting to a central double ring (as shown in formula b) represents the substituent R. y It can be substituted at any substituted or reasonable position on the ring it is connected to (such as ring H in equation b). For example, equation b represents that any position on ring H that can be substituted can be replaced by R. y Replacement, as in formula b 1~ b 5 As shown.

[0099] As described in this invention, the group "-CH2CH=CH-" has two connection sites that can be attached to the rest of the molecule, and the connection methods of the two connection sites can be interchanged. For example, formula f represents that the group -CH2CH=CH- can be attached to the rest of the molecule through either the E-terminus or the E'-terminus.

[0100] The term "pharmaceuticalally acceptable" refers to molecular entities and compositions that are physiologically tolerable when administered to humans and generally do not produce allergic or similar undesirable reactions, such as gastrointestinal upset, dizziness, etc. Preferably, as used herein, the term "pharmaceuticalally acceptable" means approved by a federal regulatory agency or national government, or listed in the United States Pharmacopeia or other generally recognized pharmacopoeia for use in animals, and more particularly in humans.

[0101] The term "pharmaceutically acceptable salt" as used in this invention refers to both organic and inorganic salts of the compounds of this invention. Pharmaceutically acceptable salts are well-known in the field, as described in the literature: SMBerge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66: 1-19. Salts formed from pharmaceutically acceptable non-toxic acids include, but are not limited to, inorganic acid salts formed by reactions with amino groups, such as hydrochlorides, hydrobromic acids, phosphates, sulfates, and perchlorates, and organic acid salts such as acetates, oxalates, maleates, tartrates, citrates, succinates, and malonates, or these salts obtained by other methods described in the literature, such as ion exchange. This invention also contemplates the formation of quaternary ammonium salts from any compound containing an N group. Water-soluble or oil-soluble or dispersed products can be obtained through quaternization. Pharmaceutically acceptable salts further include suitable, non-toxic ammonium, quaternary ammonium salts, and amine cations that resist the formation of equilibrium ions, such as halides, hydroxides, carboxylates, sulfates, phosphates, nitrates, C1-C8 sulfonates, and aromatic sulfonates.

[0102] The term "carrier" refers to a diluent, excipient, excipient, or matrix that is administered together with the compound. These drug carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, plant, or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc. Aqueous and aqueous solutions, saline solutions, and aqueous glucose and glycerol solutions are preferred as carriers, particularly for injectable solutions. Suitable drug carriers are described in EW Martin's "Remington's Pharmaceutical Sciences".

[0103] As used in this invention, the term "prodrug" refers to the conversion of a compound in vivo into a compound represented by formula (I), (II-1), or (II-2). Such conversion is influenced by the hydrolysis of the prodrug in the blood or its enzymatic conversion into the parent structure in the blood or tissues. The prodrug compounds of this invention can be esters; among existing inventions, esters that can serve as prodrugs include phenyl esters and aliphatic (C) esters. 1-24Esters, acyloxymethyl esters, carbonates, carbamates, and amino acid esters. For example, a compound containing a hydroxyl group can be acylated to yield a prodrug form. Other prodrug forms include phosphate esters, such as those obtained by phosphorylation of a hydroxyl group on the parent compound.

[0104] "Metabolic products" refer to the products obtained from the metabolism of a specific compound or its salt in vivo. The metabolites of a compound can be identified using techniques known in the art, and their activity can be characterized by experimental methods as described in this invention. Such products can be obtained by administering the compound through oxidation, reduction, hydrolysis, acylation, deacylation, esterification, defatting, enzymatic cleavage, etc. Accordingly, this invention includes the metabolites of compounds, including metabolites produced by sufficiently exposing the compounds of this invention to mammals for a period of time.

[0105] In this invention, "solvent" refers to an association formed by one or more solvent molecules with the compound of this invention. Solvents that form solvates include, but are not limited to, water, isopropanol, ethanol, methanol, dimethyl sulfoxide, ethyl acetate, acetic acid, and aminoethanol. The term "hydrate" refers to an association formed when the solvent molecules are water.

[0106] When the solvent is water, the term "hydrate" may be used. In one embodiment, a molecule of the compound of the present invention may bind to one water molecule, such as a monohydrate; in another embodiment, a molecule of the compound of the present invention may bind to more than one water molecule, such as a dihydrate; and in yet another embodiment, a molecule of the compound of the present invention may bind to fewer than one water molecule, such as a hemihydrate. It should be noted that the hydrates of the present invention retain the bioavailability of the non-hydrated form of the compound.

[0107] As used in this invention, the term "treatment" refers to any disease or condition, and in some embodiments, it means improving the disease or condition (i.e., slowing down or stopping or alleviating the development of the disease or at least one of its clinical symptoms). In other embodiments, "treatment" means alleviating or improving at least one bodily parameter, including bodily parameters that may not be perceived by the patient. In still other embodiments, "treatment" means regulating the disease or condition physically (e.g., stabilizing perceptible symptoms) or physiologically (e.g., stabilizing bodily parameters) or both. In still other embodiments, "treatment" means preventing or delaying the onset, occurrence, or worsening of the disease or condition.

[0108] The term "therapeutic effective dose" refers to the amount of a compound that is sufficient to treat a disease when administered to a subject. The "therapeutic effective dose" can vary depending on the compound, the disease and its severity, and the condition, age, weight, and sex of the subject being treated.

[0109] Unless otherwise stated, all suitable isotopic variations, stereoisomers, tautomers, solvates, metabolites, pharmaceutically acceptable salts, and prodrugs of the compounds of this invention are included within the scope of this invention.

[0110] In the structures disclosed in this invention, when the stereochemistry of any particular chiral atom is not specified, all stereoisomers of that structure are considered within the scope of this invention and are included in this invention as disclosed compounds. When the stereochemistry is indicated by a solid wedge or dashed line representing a particular configuration, the stereoisomers of that structure are thus clearly defined.

[0111] The nitrogen oxides of the compounds of this invention are also included within the scope of this invention. The nitrogen oxides of the compounds of this invention can be prepared by oxidizing the corresponding nitrogen-containing basic substances in the presence of an acid, such as acetic acid, using a common oxidizing agent (e.g., hydrogen peroxide) at elevated temperature, or by reacting with a peracid in a suitable solvent, such as with peracetic acid in dichloromethane, ethyl acetate, or methyl acetate, or with 3-chloroperoxybenzoic acid in chloroform or dichloromethane.

[0112] The pharmaceutically acceptable salts of the present invention can be synthesized using conventional chemical methods from a parent compound, a basic or acidic moiety. Generally, these salts can be prepared by reacting the free acidic form of these compounds with a stoichiometric amount of a suitable base (such as hydroxides, carbonates, bicarbonates, etc. of Na, Ca, Mg, or K), or by reacting the free basic form of these compounds with a stoichiometric amount of a suitable acid. These reactions are typically carried out in water or an organic solvent or a mixture thereof. Generally, in suitable cases, a non-aqueous medium such as diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile is required. Lists of other suitable salts can be found, for example, in “Remington’s Pharmaceutical Sciences,” 20th edition, Mack Publishing Company, Easton, Pa., (1985); and “Handbook of Pharmaceutical Salts: Properties, Selection, and Use,” Stahl and Wermuth (Wiley-VCH, Weinheim, Germany, 2002).

[0113] Furthermore, the compounds disclosed in this invention, including their salts, can also be obtained in their hydrated form or in the form of a solvent containing them (e.g., ethanol, DMSO, etc.) for their crystallization. The compounds disclosed in this invention can inherently or by design form solvates with pharmaceutically acceptable solvents (including water); therefore, this invention is intended to include both solvated and unsolvated forms.

[0114] Any structural formulas provided in this invention are intended to represent both the unenriched and isotopically enriched forms of these compounds. Isotopically enriched compounds have the structures described by the general formulas provided in this invention, except that one or more atoms are replaced by atoms having a chosen atomic weight or mass number. Exemplary isotopes that may be introduced into the compounds of this invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as... 2 H, 3 H, 11 C, 13 C, 14 C, 15 N, 17 O, 18 O, 18 F, 31 P, 32 P, 35 S, 36 Cl and 125 I. The isotopically enriched compounds of the present invention can be prepared by conventional techniques familiar to those skilled in the art or by using suitable isotope-labeled reagents instead of the previously used unlabeled reagents, as described in the examples and preparation processes of the present invention.

[0115] Unless otherwise stated, all tautomeristic forms of the compounds of this invention are included within the scope of this invention. Furthermore, unless otherwise stated, the structural formulas of the compounds described in this invention comprise enriched isotopes of one or more different atoms.

[0116] Description of the compounds of the present invention

[0117] This invention provides a PRMT5-MTA co-synergistic inhibitor that selectively inhibits the binding of SAM to PRMT5 for the treatment of related cancers. This invention also provides pharmaceutical compositions comprising this class of compounds, and the use of this class of compounds and pharmaceutical compositions thereof in the preparation of medicaments for the prevention or treatment of cancer.

[0118] The compounds of this invention exhibit excellent properties, such as good half-life, clearance rate, selectivity, bioavailability, chemical stability, metabolic stability, membrane permeability, and solubility, which can promote the reduction of side effects, the expansion of the therapeutic index, or the improvement of tolerability.

[0119] On the one hand, the present invention provides a compound that is a compound of formula (I) or a stereoisomer, tautomer, nitride, solvate, metabolite, metabolic precursor, pharmaceutically acceptable salt or prodrug of a compound of formula (I).

[0120] Among them, Y1, Y2, Z1, Z2, Z3, Z4, L, S1, S2, R, R 3 Each has the definition as described in this invention.

[0121] In some implementations, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic groups, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl; or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S; where R c It has the definition as described in this invention.

[0122] In some implementations, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-4 Alkyl, C 1-4 Heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 1-4 Halogenated alkyl or C 1-4 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4Halogenated alkyl or C 1-4 Deuterated alkyl; or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S; where R c It has the definition as described in this invention.

[0123] In other implementations, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolidine, 2-pyrrololinyl, 3- Pyrrololinyl, pyrazolinyl, pyrazoloalkyl, imidazolinyl, imidazoalkyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyridyl, dihydropyridyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CD3, -CHD2, -CH2D, -CHDCH3, -CD2CH3, -CH2CHD2, -CH2CH2D or -CH2CD3; the two Rs on C. Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH 3. -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, - CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CD3, -CHD2, -CH2D, -CHDCH3, -CD2CH3, -CH2CHD2, -CH2CH2D or -CH2CD3 or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S; where R c It has the definition as described in this invention.

[0124] In some implementations, Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-6 Alkyl or C 1-6 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6 Carbon rings or 3-10 membered heterocycles.

[0125] In some implementations, Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-4 Alkyl or C 1-4 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6Carbon rings or 3-6 membered heterocycles.

[0126] In other implementations, Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a The two Rs on the C are H, D, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br; Y2b Whether they are the same or different, each R Y2b Each can independently be H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs on C. Y2b Together with the carbon atoms attached to them, they form =O, =S, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, ethylene oxide, azacyclobutane, oxacyclobutane, thiocyclobutane, pyrrolidine, pyrrololine, pyrazolin, pyrazolidine, imidazoline, imidazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, dioxocyclopentane, dithiocyclopentane, tetrahydropyran, dihydropyran, 2H-pyran, 4H-pyran, tetrahydrothiaran, piperidine, morpholine, thiomorpholine, piperazine, dioxane, dithiazide, or thiazide.

[0127] In some implementations, Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl groups.

[0128] In some implementations, Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;RZ1 R Z2 R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl groups.

[0129] In other implementations, Z1 is N or CR. Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br.

[0130] In some embodiments, the compound of the present invention is a compound of formula (II-1) or (II-2), or a stereoisomer, geometric isomer, tautomer, nitride, hydrate, solvate, metabolite, metabolic precursor, pharmaceutically acceptable salt, or prodrug of a compound of formula (II-1) or (II-2).

[0131] Among them, L, R, R 3 R Y1a Each has the definition as described in this invention.

[0132] In some implementation schemes, R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 4 Replaced; where R d R e R f R 4 Each has the definition as described in this invention.

[0133] In some implementation schemes, R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 4 Replaced; where R d R e R f R 4 Each has the definition as described in this invention.

[0134] In other implementations, R 3 For H, D, -S(=O)2R d -NR e R f, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH 3. -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHC H2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thioheridine, pyrrolyl, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyridyl, dihydropyridyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, furanyl Imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazinyl, 1,3,5-triazinyl, pyrazolopyridine, dihydropyrroloimidazole or phenyl, wherein -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH3, -CH2SCH3, -CH2OC H2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxaziridine, thioaziridine, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-Dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiaranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxylalkyl, dithiaalkyl, thiaoxylalkyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrroleyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazine, 1,3,5-triazinyl, pyrazolopyridine, dihydropyrroleimidazole, and phenyl are each independently and optionally divided by 1, 2, 3, or 4 Rs. 4 Replaced; where R d R e R f R 4 Each has the definition as described in this invention.

[0135] In some implementations, each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10 Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 5 The replaced; or two R atoms attached to the same carbon atom 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ;where R g R h R i R p R q R 5 Each has the definition as described in this invention.

[0136] In some implementations, each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-4 Alkyl, C1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, 5-6 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6-membered heterocyclic, 5-6-membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 5 The two R atoms that are replaced or attached to the same carbon atom are replaced. 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ;where R g R h R i R p R q R 5 Each has the definition as described in this invention.

[0137] In other implementations, each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2 CH3, -OCH3, -OCH2CH3, -OCH(CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolyl, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiopheneyl, dihydrothiopheneyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopheneyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, furanyl Imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazinyl, 1,3,5-triazinyl or phenyl, wherein -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -C H2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -OCH3, -OCH2CH3, -OCH(CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiocyclobutyl, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolylyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-Dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiaranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxylalkyl, dithiaalkyl, thiaoxylalkyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrroleyl, pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazine, 1,3,5-triazinyl, and phenyl are each independently and optionally surrounded by 1, 2, 3, or 4 Rs. 5 The two R atoms that are replaced or attached to the same carbon atom are replaced. 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ;where R g R h R i R p R q R 5 Each has the definition as described in this invention.

[0138] In some implementations, each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-10 membered heterocyclic groups; wherein, the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 The cycloalkyl or 3-10 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ;where R j R k R m R s R t Each has the definition as described in this invention.

[0139] In some implementations, each R 5Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; wherein, the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 The cycloalkyl or 3-6 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ;where R j R k R m R s R t Each has the definition as described in this invention.

[0140] In some other implementations, each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH 2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -C H2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thioheridine, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolidine, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl or thiaalkyl;Among them, the -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2C H2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolylalkyl, imidazolinyl, imidazolinyl Alzolyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, and thiaalkyl are each independently and optionally surrounded by 1, 2, 3, or 4 D, -CN, -OH, F, Cl, Br, I, -CH3, -CH2CH3, - The substituents are (CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ;where R j R k R m R s R t Each has the definition as described in this invention.

[0141] In some implementation schemes, R 3 Selected from any of the following groups: H, F, -CH3, -CF3, -S(O)2CH3, cyclopropyl, -N(CH3)2,

[0142] In some implementations, R is selected from any of the following structures:

[0143] in Ring A, Ring B, X1, X2, X3, X4, X5, X6, X7, X8, R 1 R 2 m and W each have the definitions described in this invention.

[0144] In some implementations, R is selected from any of the following structures:

[0145] Among them, R X1 R X2 R X3 R X8 R 1 R 2 Each of and m has the definition as described in this invention.

[0146] In some implementations, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl groups.

[0147] In some implementations, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups.

[0148] In other implementations, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 RX3 and R X8 Each of these can be independently represented as H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH 2NHCH2CH3, -OCH2CH2NHCH2CH3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH 2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br.

[0149] In some implementations, X4 is N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl groups.

[0150] In some implementations, X4 is N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups.

[0151] In other implementations, X4 is N, C, or CRX4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br.

[0152] In some implementations, W stands for O, S, NR. W1 or C(R) W2 )2; R on N W1 For H, D, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Haloalkyl; 2 Rs on C W2 Whether they are the same or different, each R W2 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl group; or two R groups on C. W2 Together with the carbon atoms they are attached to, they form =O or =S.

[0153] In some implementations, W stands for O, S, NR. W1 or C(R) W2 )2; R on N W1 For H, D, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Haloalkyl; 2 Rs on C W2 Whether they are the same or different, each R W2 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl group; or two R groups on C.W2 Together with the carbon atoms they are attached to, they form =O or =S.

[0154] In other implementations, W represents O, S, and NR. W1 or C(R) W2 )2; R on N W1 For H, D, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -C 2 R on C W2 Whether they are the same or different, each R W2 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs on C. W2 Together with the carbon atoms they are attached to, they form =O or =S.

[0155] In some implementations, ring A and ring B are each independently designated as C. 3-6 Carbocyclic rings, 3-10 membered heterocyclic rings, 5-10 membered heteroaromatic rings, or C 6-10 Aromatic ring.

[0156] In some implementations, ring A and ring B are each independently designated as C. 3-6 Carbon rings, 3-6 membered heterocyclic rings, 5-6 membered heteroaromatic rings, or benzene rings.

[0157] In other embodiments, ring A and ring B are each independently cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, benzene ring, furan, imidazole, isoxazole, oxazole, pyrrole, pyridine, pyrimidine, pyridazine, thiazole, tetrazolium, triazole, thiophene, pyrazole, isothiazole, oxadiazole, 1,2,3-triazole, thiodiazole, pyrazine, 1,3,5-triazine, 1,2,4 - Triazine, oxazine, ethylene oxide, azacyclobutane, oxacyclobutane, thiocyclobutane, pyrrolidine, pyrrololine, pyrazoline, pyrazolidine, imidazoline, imidazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, dioxacyclopentane, dithiocyclopentane, tetrahydropyran, dihydropyran, 2H-pyran, 4H-pyran, tetrahydrothiaran, piperidine, morpholine, thiomorpholine, piperazine, dioxane, dithiazide, or thiazide.

[0158] In some implementation schemes, R 1 H, D, halogen, -CN, -NR a R b C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkyl groups; wherein R a R b It has the definition as described in this invention.

[0159] In some implementation schemes, R 1 H, D, halogen, -CN, -NR a R b C 1-4 Alkyl, C 1-4 Alkoxy or C 1-4 Halogenated alkyl groups; wherein R a R b It has the definition as described in this invention.

[0160] In other implementations, R 1 For H, D, F, Cl, Br, I, -CN, -NR a R b -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; where R a R b It has the definition as described in this invention.

[0161] In some implementations, each R2 Each is independently D, halogen, -CN, -NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms they are attached to, they form =O or =S.

[0162] In some implementation schemes, R 2 Each is independently D, halogen, -CN, -NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl or C 1-4 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms they are attached to, they form =O or =S.

[0163] In other implementations, R 2 Each of these can be independently represented as D, F, Cl, Br, I, -CN, -NO2, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CH=CH2, -CH2CH=CH2, -CH=CH-CH3, -C≡CH, -CH2C≡CH, -C≡C-CH3, -OCH3, -OCH2CH3, or -OCH(CH3)2, or two R atoms attached to the same carbon atom. 2 Together with the carbon atoms they are attached to, they form =O or =S.

[0164] In some implementation schemes, each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Heteroalkyl or C 1-6 Halogenated alkyl groups.

[0165] In some implementation schemes, each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups.

[0166] In other implementations, each R a R b R c R d R e R f R g R h R i R j R k R m Independently, it can be H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br.

[0167] In some implementation schemes, each R p R q R s R t Independent of H, D, halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl or C 1-6 Halogenated alkyl groups.

[0168] In some implementation schemes, each R p R q R s R t Independent of H, D, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups.

[0169] In other implementations, each R p R q R s R t Independently H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH 2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br.

[0170] In some implementations, L is C 2-6 imide or C 2-6 Alynyl group.

[0171] In some implementations, L is C 2-4 imide or C 2-4 Alynyl group.

[0172] In other implementations, L is -CH=CH-, -CH2CH=CH-, -CH2CH=CHCH2-, -CH2CH2CH=CH-, -C≡C-, -CH2C≡C-, -CH2CH2C≡C-, or -CH2C≡CCH2-.

[0173] In some implementation schemes, It can be a single bond or a double bond.

[0174] In some implementations, the values ​​of S1 and S2 are positive integers, and the sum of S1 and S2 is 2, 3, or 4.

[0175] In some implementations, S1 is 1, 2, or 3, S2 is 1, 2, or 3, and the sum of S1 and S2 is 2, 3, or 4.

[0176] In some implementations, m is 0, 1, 2, 3, 4, 5, or 6.

[0177] In some embodiments, the compound of the present invention is a structure or a stereoisomer, tautomer, nitride, solvate, metabolite, pharmaceutically acceptable salt, or prodrug that is one of the following:

[0178] On the other hand, the present invention provides a pharmaceutical composition comprising the compound described herein or a stereoisomer, tautomer, nitride, solvate, metabolite, pharmaceutically acceptable salt, or prodrug; optionally, it further comprises a pharmaceutically acceptable carrier.

[0179] On the other hand, the present invention provides the use of the compounds or pharmaceutical compositions described herein in the preparation of a medicament, wherein the medicament is used to protect against, treat, cure or alleviate cancer in a patient.

[0180] On the other hand, the present invention provides compounds or pharmaceutical compositions described herein for the prevention, treatment or treatment of cancer.

[0181] On the other hand, the present invention provides a method for preventing, treating or treating cancer, comprising administering a patient a therapeutically effective amount of the compound or pharmaceutical composition described herein.

[0182] In some embodiments, the cancers described in this invention are MTAP deficiency-related cancers; optionally, the MTAP deficiency-related cancers are ovarian cancer, lung cancer, lymphoma, glioblastoma, colon cancer, melanoma, gastric cancer, bile duct cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0183] On the other hand, the present invention relates to methods for the preparation, separation and purification of compounds represented by formula (I), (II-1) or (II-2).

[0184] Unless otherwise indicated, all stereoisomers, geometric isomers, tautomers, nitrides, hydrates, solvates, metabolites, salts, and pharmaceutically acceptable prodrugs of the compounds of this invention are within the scope of this invention.

[0185] Specifically, the salt is a pharmaceutically acceptable salt. The term "pharmaceutically acceptable" means that the substance or composition must be chemically or toxicologically appropriate in relation to the other components of the formulation and the mammal intended for treatment.

[0186] The salts of the compounds of the present invention also include salts of intermediates used for the preparation or purification of compounds of formula (I), (II-1) or (II-2) or salts of enantiomers isolated from compounds of formula (I), (II-1) or (II-2), but are not necessarily pharmaceutically acceptable salts.

[0187] If the compound of the present invention is basic, the desired salt can be prepared by any suitable method provided in the literature, for example, using inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, and phosphoric acid, etc. Alternatively, organic acids such as acetic acid, maleic acid, succinic acid, mandelic acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, and salicylic acid can be used; pyranonic acids such as glucuronic acid and galacturonic acid; α-hydroxy acids such as citric acid and tartaric acid; amino acids such as aspartic acid and glutamic acid; aromatic acids such as benzoic acid and cinnamic acid; sulfonic acids such as p-toluenesulfonic acid, ethanesulfonic acid, etc.

[0188] If the compounds of the present invention are acidic, the desired salts can be prepared by suitable methods, such as using inorganic or organic bases, such as ammonia (primary, secondary, and tertiary ammonia), alkali metal hydroxides, or alkaline earth metal hydroxides, etc. Suitable salts include, but are not limited to, organic salts derived from amino acids, such as glycine and arginine; ammonia, such as primary, secondary, and tertiary ammonia; and cyclic ammonia, such as piperidine, morpholine, and piperazine, etc.; and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

[0189] Pharmaceutical compositions, formulations, administration and uses of the compounds of the present invention

[0190] According to another aspect, the pharmaceutical compositions of the present invention are characterized by compounds represented by formula (I), (II-1), or (II-2), compounds listed in the present invention, or compounds of the embodiments, and pharmaceutically acceptable carriers. The compounds of the present invention exist in free form or as suitable, pharmaceutically acceptable derivatives. According to the present invention, pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable prodrugs, salts, esters, salts of esters, or any other adducts or derivatives that can be administered directly or indirectly as needed by a patient, compounds described in other aspects of the present invention, their metabolites, or their residues. The amounts of compounds in the compositions of the present invention are effective in treating or alleviating cancer in patients.

[0191] As described in this invention, pharmaceutically acceptable compositions of this invention further comprise pharmaceutically acceptable carriers, excipients, or excipients, such as those used in this invention, including any solvent, diluent, or other liquid excipient, dispersant or suspending agent, surfactant, isotonic agent, thickener, emulsifier, preservative, solid binder, or lubricant, etc., suitable for a particular target dosage form. As described in the following literature: In Remington: The Science and Practice of Pharmacy, 21st edition, 2005, ed. D.B. Troy, Lippincott Williams & Wilkins, Philadelphia, and Encyclopedia of Pharmaceutical Technology, eds. J. Swarbrick and J.C. Boylan, 1988-1999, Marcel Dekker, New York, the contents of this literature demonstrate that different carriers can be used in the formulation of pharmaceutically acceptable compositions and their known methods of preparation. Except for any conventional carrier media that are incompatible with the compounds of the present invention, such as any adverse biological effects produced or interactions with any other component of a pharmaceutically acceptable composition that occur in a harmful manner, their use is also within the scope of this invention.

[0192] Substances that can serve as pharmaceutically acceptable carriers include, but are not limited to, ion exchangers, aluminum, aluminum stearate, lecithin, serum proteins such as human serum albumin, buffering agents such as phosphates, glycine, sorbic acid, potassium sorbate, mixtures of partial glycerides of saturated vegetable fatty acids, water, salts or electrolytes such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, polyacrylates, waxes, polyethylene-polyoxypropylene-blocking polymers, lanolin, sugars such as lactose, glucose, and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as carboxymethyl cellulose. Sodium thiosulfate, ethyl cellulose and cellulose acetate; gum powder; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol and polyethylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffers such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic salts; Ringer's solution; ethanol, phosphate buffer solution, and other non-toxic and suitable lubricants such as sodium lauryl sulfate and magnesium stearate, colorants, release agents, coatings, sweeteners, flavorings and spices, preservatives and antioxidants.

[0193] Preferably, the compound is mixed with a suitable drug diluent, excipient, or carrier (in this case, a drug carrier) selected according to the form of administration and conventional pharmaceutical practice, and the administration method may be oral tablets, capsules, elixirs, syrups, etc.

[0194] For example, for oral administration in tablet or capsule form, the active pharmaceutical ingredient can be conjugated with an orally administered, non-toxic, pharmaceutically acceptable inert carrier, such as lactose, starch, sucrose, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, calcium sulfate, mannitol, sorbitol, etc.; for oral administration in liquid form, the oral pharmaceutical ingredient can be conjugated with any orally administered, non-toxic, pharmaceutically acceptable inert carrier, such as ethanol, glycerin, water, etc. Furthermore, suitable binders, lubricants, dissolving agents, and colorants can be added to the mixture when needed or necessary. Suitable binders include starch, gelatin, natural sugars such as glucose or β-lactose, corn sweeteners, natural and synthetic gums such as gum arabic, astragalus gum, or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, etc. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, etc. Decomposing agents include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, etc.

[0195] The compounds of this invention can be administered in oral dosage forms, such as tablets, capsules (each comprising a sustained-release or timed-release formulation), pills, powders, granules, elixirs, tinctures, suspensions, syrups, and emulsifiers. They can also be administered intravenously (in pills or infusions), intraperitoneally, subcutaneously, or intramuscularly, all dosage forms used being well known to those skilled in the art of pharmacy. They can be administered alone, but generally a pharmaceutical carrier will be selected for co-administration based on the chosen route of administration and standard pharmaceutical practice.

[0196] The compounds of the present invention can be administered intranasally via a suitable intranasal carrier or transdermally via a transdermal patch. When administered via a transdermal delivery system, the dose is continuous rather than intermittent throughout the course of treatment.

[0197] The compounds of this invention can also be administered in the form of liposome delivery systems, such as small monolayer vesicles, large monolayer vesicles, and multilayer vesicles. Liposomes can be formed from different phospholipids, such as cholesterol, stearamine, or phosphatidylcholine.

[0198] The compounds of this invention are also coupled with soluble polymers that serve as targeted drug carriers. Such polymers include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropyl methacrylate-phenol, polyhydroxyethyl asparagine, or polyvinyl oxide-polylysine substituted with palmitoyl residues. Furthermore, the compounds of this invention can be coupled with a class of biodegradable polymers for controlled drug release, such as polylactic acid, polyglycolic acid, copolymers of polylactic acid and polyglycolic acid, polycaprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydropyran, polycyanoacrylates, and crosslinked or amphiphilic blocking copolymers of hydrogels.

[0199] The dosing regimen of the compounds of this invention will vary depending on various known factors, such as the pharmacokinetic characteristics and patterns of the specific agent and the route of administration; the recipient's race, age, sex, health status, medical condition, and weight; the nature and severity of symptoms; the types of concurrent treatments; the frequency of treatment; the route of administration; the patient's renal and hepatic function; and the desired effect. A physician or veterinarian can make a decision and prescribe an effective dose of the drug to prevent, counteract, or halt the development of cancer.

[0200] When the compounds of the present invention are administered together with other therapeutic agents, the amount of each component in a typical daily dose and typical dosage form may generally be reduced relative to the usual dose when administered alone, taking into account the additional or synergistic effects of the therapeutic agents when administered in combination.

[0201] The dosing regimen of the compounds of this invention will vary depending on various known factors, such as the pharmacokinetic characteristics and patterns of the specific agent and the route of administration; the recipient's race, age, sex, health status, medical condition, and weight; the nature and severity of symptoms; the types of concurrent treatments; the frequency of treatment; the route of administration; the patient's renal and hepatic function; and the desired effect. A physician or veterinarian can make a decision and prescribe an effective dose of the drug to prevent, counteract, or halt the development of cancer.

[0202] The compositions and methods provided by this invention are particularly considered for use in inhibiting PRMT5 activity in cells in vivo. In some embodiments, cells requiring inhibition of PRMT5 activity are contacted in vivo with a therapeutically effective amount of the compound of this invention or a pharmaceutically acceptable salt thereof to negatively modulate PRMT5 activity.

[0203] The compounds and compositions of this invention can be used to treat a variety of cancers, including but not limited to prostate cancer, breast cancer, brain cancer, skin cancer, cervical cancer, testicular cancer, lymphoma, glioblastoma, melanoma astrocytoma, colon cancer, rectal cancer, endometrial cancer, esophageal cancer, stomach cancer, head and neck cancer, hepatocellular carcinoma, laryngeal cancer, lung cancer, oral cancer, ovarian cancer, prostate cancer, thyroid cancer, sarcoma, bladder cancer, pancreatic cancer, liver cancer, bile duct cancer, and glioblastoma.Specifically, these compounds can be used to treat the following diseases: Heart: sarcoma, myxoma, rhabdomyosarcoma, fibroma, lipoma, and teratoma; Lung: bronchogenic carcinoma, alveolar carcinoma, bronchial adenoma, sarcoma, lymphoma, chondromatous hamartoma, mesothelioma; Gastrointestinal tract: esophagus (squamous cell carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach (carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal adenocarcinoma, insulinoma, glucagonoma, gastrinoma, carcinoid tumor, viperoma), small intestine (adenocarcinoma, lymphoma, carcinoid tumor, Kaposi's sarcoma, leiomyosarcoma, hemangioma, lipoma, neurofibroma, fibroma), large intestine (adenocarcinoma, tubular adenoma, villous adenoma, hamartoma, leiomyosarcoma); [The text abruptly ends here, likely due to an incomplete translation or source material.] Urogenital tract: Kidneys (adenocarcinoma, nephroblastoma, lymphoma, leukemia), bladder and urethra (squamous cell carcinoma, transitional cell carcinoma, adenocarcinoma), prostate (adenocarcinoma, sarcoma), testes (seminomatous cyst, teratoma, embryonal carcinoma, teratoma, choriocarcinoma, sarcoma, stromal cell carcinoma, fibroma, fibroadenoma, adenoma-like tumor, lipoma); Liver: Hepatocellular carcinoma (hepatocellular carcinoma), bile duct carcinoma, hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma; Bile duct: Gallbladder carcinoma, ampullary carcinoma, bile duct carcinoma; Bone: Osteosarcoma, fibrosarcoma, malignant fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant lymphoma, multiple myeloma, malignant giant cell tumor, chordoma, osteochondral exostosis, benign soft tissue tumors. Osteoma, chondroblastoma, chondromyxoid fibroma, osteoid osteoma, and giant cell tumor; Nervous system: Skull (osteoma, hemangioma, granuloma, xanthoma, osteitis deformans), Meninges (meningioma, meningeal sarcoma, glioma), Brain (astrocytoma, medulloblastoma, glioma, ependymoma, germ cell tumor, glioblastoma multiforme, oligodendroglioma, schwannoma, retinoblastoma, congenital tumor), Spinal cord neurofibroma, meningioma, glioma, sarcoma; Gynecological: Uterus (endometrial cancer), Cervix (cervical cancer, pretumoral cervical dysplasia), Ovary (ovarian cancer, granulosa cell tumor, Sertoli stromal tumor, etc.) Germ cell tumors, malignant teratomas), vulva (squamous cell carcinoma, intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma), vagina (clear cell carcinoma, squamous cell carcinoma, botryoid sarcoma), fallopian tubes (cancer); hematologic diseases: blood (myeloid leukemia (acute and chronic), acute lymphoblastic leukemia, chronic lymphocytic leukemia, myeloproliferative disorders, multiple myeloma, myelodysplastic syndrome), Hodgkin's disease, non-Hodgkin's lymphoma (malignant lymphoma); skin diseases: malignant melanoma, basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, hydatidiform mole, dysplastic nevus, lipoma, hemangioma, dermatofibroma, keloid, psoriasis; and adrenal diseases: neuroblastoma.

[0204] In some implementations, the cancer is MTAP-related cancer.

[0205] In some implementations, the MTAP deficiency-related cancers are ovarian cancer, lung cancer, lymphoma, glioblastoma, colon cancer, melanoma, gastric cancer, bile duct cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.

[0206] General Synthesis Process

[0207] Examples are listed below to describe the present invention. However, it should be understood that the present invention is not limited to these examples, but merely provides a method for practicing the present invention.

[0208] Generally, the compounds of the present invention can be prepared by the methods described herein, unless otherwise specified, wherein the substituents are defined as described herein. The following reaction schemes and examples are provided to further illustrate the content of the present invention.

[0209] Those skilled in the art will recognize that the chemical reactions described in this invention can be suitably used to prepare other compounds of this invention, and that other methods for preparing the compounds of this invention are considered to be within the scope of this invention. For example, the synthesis of those non-illustrative compounds according to this invention can be successfully accomplished by those skilled in the art through modification methods, such as by appropriately protecting interfering groups, by utilizing other known reagents besides those described in this invention, or by making some conventional modifications to the reaction conditions. Furthermore, the reactions disclosed in this invention or the known reaction conditions are also generally accepted to be applicable to the preparation of other compounds of this invention.

[0210] In the examples described below, unless otherwise specified, all temperatures are in degrees Celsius (°C). Room temperature in the examples refers to 15°C to 30°C; in some examples, room temperature is 20°C to 30°C. Unless otherwise specified, common reagents are commercially available, such as anhydrous tetrahydrofuran, anhydrous dioxane, anhydrous acetonitrile, and anhydrous dichloromethane, as well as toluene, diethyl ether, ethyl acetate, petroleum ether, n-hexane, N,N-dimethylacetamide, and N,N-dimethylformamide, etc.

[0211] The following reactions are generally conducted at room temperature and pressure, or under positive nitrogen pressure, or in anhydrous solvent with a drying tube attached (unless otherwise specified). All reaction flasks are sealed with suitable rubber stoppers, and the substrate is injected via a syringe. All glassware is dried.

[0212] The chromatographic column used was a silica gel column. The silica gel (300-400 mesh) was purchased from Qingdao Ocean Chemical Plant.

[0213] 1 H NMR spectra were recorded using a Bruker 400MHz or 600MHz nuclear magnetic resonance spectrometer. 1 ¹H NMR spectra are performed using CDCl₃, DMSO-d₆, CD₃OD, or acetone-d₆ as solvents (in ppm), with TMS (0 ppm) or chloroform (7.26 ppm) as reference standards. When multiplets are observed, the following abbreviations are used: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), br (broadened), brs (broadened singlet), dd (doublet of doublets), dt (doublet of triplets). The coupling constant J is expressed in Hertz (Hz).

[0214] The determination conditions for low-resolution mass spectrometry (MS) data were as follows: Agilent 6120 quadrupole HPLC-MS (column model: Zorbax SB-C18, 2.1×15mm, 3.5 μm, 6 min, flow rate 0.6 mL / min; mobile phase: A phase (aqueous phase): water-acetonitrile-formic acid = 950:50:1, B phase (organic phase): acetonitrile:formic acid = 1000:1, gradient: 0 min: A phase 100%, 2 min: A phase 0%, 3.5 min: A phase 0%), electrospray ionization (ESI) at 210 nm / 254 nm, detection by UV.

[0215] Pure compounds were detected using UV at 210 nm / 254 nm using an Agilent 1260 pre-HPLC or a Calesep pump 250 pre-HPLC (column model: NOVASEP 50 / 80 mm DAC).

[0216] The following abbreviations are used throughout this invention: THF (tetrahydrofuran), DCM (dichloromethane), TEA (triethylamine), TFA (trifluoroacetic acid), DMSO (dimethyl sulfoxide), LDA (diisopropylaminolithium), KHMDS (bis(trimethylsilyl)aminopotassium), NaHMDS (bis(trimethylsilyl)aminosodium), CAN (bis(trimethylsilyl)aminosodium), DIPEA (cerium ammonium nitrate), DEAD (N,N-diisopropylethylamine), DMAP (diethyl azodicarbonate), EA (4-dimethylaminopyridine), PE (ethyl acetate), IPA (petroleum ether), HATU (isopropanol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (PPh3), PdCl2(PPh3)2-bis(triphenyl)phosphine palladium dichloride (LiHMDS), KHMDS (bis(trimethylsilyl)aminolithium), TBAF (bis(trimethyl)silyl)aminopotassium), Boc (tetrabutylammonium fluoride), t-Butyloxycarbonyl (t-Bu), t-Butyl (rt;rt) The following reaction scheme describes the steps for preparing the compounds disclosed in this invention at room temperature.

[0217] Reaction scheme (1)

[0218] Compound B1 and compound B2 undergo a Sonogashira coupling reaction under anhydrous and oxygen-free conditions and suitable conditions (such as an inorganic base (preferably triethylamine), cuprous iodide, and a palladium catalyst (preferably bis(triphenylphosphine)palladium dichloride)) to give compound B3; compound B3 undergoes a nucleophilic substitution reaction with compound B4 under strong base conditions (preferably lithium bis(trimethylsilylaminosylamino) or sodium bis(trimethylsilylaminosylamino)) and low temperature conditions (such as -5°C) to give compound B5; the nitro group on compound B5 is reduced under reducing conditions (preferably iron powder or zinc powder) to give amino compound B6;

[0219] Option 1), compound B6 is reduced to its ester group under reducing agent (preferably lithium borohydride) conditions to obtain compound B7-1; the -NH2 group of compound B7-1 is converted to a halogen (preferably bromine or iodine) via a diazo reaction, and then undergoes an intramolecular CO coupling reaction with -CH2OH under palladium catalysis (preferably palladium acetate or Tris(dibenzylideneacetone)dipalladium) to obtain compound B8-1; or

[0220] Option 2), compound B6 is hydrolyzed under alkaline conditions (preferably lithium hydroxide) to give compound B7-2; compound B7-2 undergoes intramolecular amide condensation of -NH2 and -COOH under the conditions of a condensing agent (preferably HATU), and then reacts with R under alkaline conditions (preferably sodium hydride). Y1a -A1 reaction yields compound B8-2;

[0221] Compound B8-1 or B8-2 is deprotected by the protecting group Boc under acidic conditions (such as trifluoroacetic acid) to obtain compound B9-1 or B9-2. Compound B9-1 or B9-2 is then condensed with compound R-COOH under alkaline conditions (such as TEA, DIPEA, etc.) and condensing agent (such as HATU) to obtain compound (I-1) or (I-2).

[0222] Among them, L, Z1, Z2, Z3, Z4, R, R 3 R Y1a S1 and S2 each have the definitions described in this invention; A1 is a halogen, preferably bromine and iodine; A2 is a halogen, preferably F.

[0223] Reaction scheme (2)

[0224] Compound C1 and compound B2 undergo a Sonogashira coupling reaction under anhydrous and oxygen-free conditions and suitable conditions (such as an inorganic base (preferably triethylamine), cuprous iodide, and a palladium catalyst (preferably bis(triphenylphosphine)palladium dichloride)) to give compound C3; compound C3 undergoes a nucleophilic substitution reaction with compound C4 under strong base (preferably potassium bis(trimethylsilylamino)) and low temperature conditions (such as -10°C) to give compound C5; compound C5 reduces the cyano group under alkaline conditions with an oxidizing agent (preferably hydrogen peroxide) and potassium carbonate to give amide compound C6; compound C6 undergoes a coupling cyclization reaction catalyzed by a copper reagent (preferably cuprous oxide) to give compound C7; compound C7 reacts with R under alkaline conditions (preferably sodium hydride) with R Y1aAfter the -A1 reaction yields compound B8-2, compound B8-2 is deprotected by the protecting group Boc under acidic conditions (such as trifluoroacetic acid) to obtain compound B9-2. Compound B9-2 then undergoes a condensation reaction with compound R-COOH under alkaline conditions (such as TEA, DIPEA, etc.) and a condensing agent (such as HATU) to obtain compound (I-2).

[0225] Among them, L, Z1, Z2, Z3, Z4, R, R 3 R Y1a S1 and S2 each have the definitions described in this invention; A1 is a halogen, preferably bromine and iodine; A2 is a halogen, preferably F. Example

[0226] Example 1: 1-(4-amino-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl)-6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0227] Step 1: Synthesis of 1-cyclobutyl-4-ethynyl-1H-pyrazole

[0228] A solution of 4-pyrazole-acetylene (5 g, 54.3 mmol) in acetonitrile (100 mL) was added with cyclobutyl bromide (11 g, 81.4 mmol) and potassium carbonate (15 g, 108.6 mmol), and the mixture was heated to 50 °C and reacted overnight. After the reaction was complete, the mixture was poured into ethyl acetate (300 mL), washed with saturated brine (20 mL × 3), and the organic layer was evaporated to dryness and then subjected to column chromatography to obtain 6.6 g of the target product as a white solid, with a yield of 83.2%. LC-MS (ESI, pos.ion) m / z: 147.1 [M+H] + .

[0229] Step 2: Synthesis of 1-cyclobutyl-4-((4-fluoro-3-nitrophenyl)ethynyl)-1H-pyrazole

[0230] To a tetrahydrofuran solution (250 mL) of 1-cyclobutyl-4-ethynyl-1H-pyrazole (6.6 g, 45.2 mmol) and 4-bromo-1-fluoro-2-nitrobenzene (9.44 g, 42.9 mmol), cuprous iodide (430 mg, 2.26 mmol), triethylamine (13.7 g, 135.4 mmol), and palladium dichloride dichloride (3.17 g, 4.51 mmol) were added sequentially. The reaction was carried out under nitrogen protection at room temperature. After the reaction was complete, the reaction solution was poured into ethyl acetate (500 mL), washed with saturated brine (50 mL × 3), the organic layer was dried, concentrated under reduced pressure, and the residue was purified by silica gel column chromatography to give 10.6 g of a pale yellow solid product, with a yield of 82.3%. LC-MS (ESI, pos.ion) m / z: 286.1 [M+H] + .

[0231] Step 3: Synthesis of 1-tert-butyl-3-ethyl-3-(4-((1-cyclobutyl-1H-pyrazole-4-yl)ethynyl)-2-nitrophenyl)azacyclobutane-1,3-dicarboxylate

[0232] At -5°C, under nitrogen protection, lithium bis(trimethylsilylamino)amine (90 mL, 1.0 M) was slowly added dropwise to an anhydrous tetrahydrofuran solution (500 mL) of 1-cyclobutyl-4-((4-fluoro-3-nitrophenyl)ethynyl)-1H-pyrazole (10.6 g, 37.2 mmol) and 1-(tert-butyl)-3-ethylazacyclobutane-1,3-dicarboxylic acid ester (12.8 g, 55.7 mmol) and the reaction was continued overnight. The reaction was then allowed to proceed at room temperature until complete. The reaction solution was poured into ethyl acetate (1000 mL) and washed with saturated brine (30 mL × 6). The organic layer was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by rapid silica gel column chromatography to give 2.5 g of a yellow solid product, yield 13.6%. LC-MS (ESI, pos.ion) m / z: 495.2 [M+H] + .

[0233] Step 4: Synthesis of 1-tert-butyl-3-ethyl-3-(2-amino-4-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)phenyl)azacyclobutane-1,3-dicarboxylate

[0234] Iron powder (1.4 g, 25.3 mmol) and acetic acid (0.5 mL) were added to a mixed solvent of 1-tert-butyl-3-ethyl-3-(4-((1-cyclobutyl-1H-pyrazole-4-yl)ethynyl)-2-nitrophenyl)azacyclobutane-1,3-dicarboxylate (2.5 g, 5.06 mmol) in 50 mL of ethanol and 10 mL of water. The mixture was heated to 65 °C and reacted. After the reaction was complete, the mixture was filtered while hot. Most of the ethanol solvent was removed from the filtrate, and the filtrate was then added to 350 mL of ethyl acetate. The mixture was washed with saturated sodium bicarbonate solution (25 mL × 5). The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography to obtain 1.82 g of the target product as a light brown solid, with a yield of 77.5%. LC-MS (ESI, pos.ion) m / z: 465.2 [M+H] + .

[0235] Step 5: Synthesis of 3-(2-amino-4-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)phenyl)-1-(tert-butoxycarbonyl)azacyclobutane-3-carboxylic acid

[0236] Lithium hydroxide (464 mg, 19.4 mmol) was added to a mixed solvent of 1-tert-butyl-3-ethyl 3-(2-amino-4-((1-cyclobutyl-1H-pyrazole-4-yl)ethynyl)phenyl)azacyclobutane-1,3-dicarboxylate (1.8 g, 3.87 mmol) in tetrahydrofuran (20 mL) and water (50 mL), and the reaction was carried out at room temperature. After the reaction was completed, the tetrahydrofuran was removed by concentration under reduced pressure, and the pH was adjusted to 5 by adding 2.0 M hydrochloric acid aqueous solution. The mixture was then filtered, and the filter cake was dried to give 1.2 g of the target product as a light gray solid, with a yield of 70.9%. LC-MS (ESI, pos.ion) m / z: 437.2 [M+H] + .

[0237] Step 6: Synthesis of 1-tert-butyl6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylate

[0238] N,N-diisopropylethylamine (1.07 g, 8.26 mmol) was added to dichloromethane (80 mL) containing 3-(2-amino-4-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)phenyl)-1-(tert-butoxycarbonyl)azacyclobutane-3-carboxylic acid (1.2 g, 2.75 mmol) and HATU (1.26 g, 3.3 mmol), and the mixture was stirred at room temperature. After the reaction was complete, the system was concentrated under reduced pressure, and the residue was purified by column chromatography to give 520 mg of a light brown solid, with a yield of 45.2%. LC-MS (ESI, pos.ion) m / z: 419.2 [M+H]+ .

[0239] Step 7: Synthesis of tert-butyl 6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylate

[0240] Sodium hydride (55 mg, 1.37 mmol, 60%) was added to anhydrous tetrahydrofuran (30 mL) containing 520 mg (1.2 mmol) of 1-tert-butyl-6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylate. The mixture was stirred for 30 minutes, followed by the addition of 221 mg (1.55 mmol) of iodomethane and stirring for another 10 minutes. The mixture was then allowed to react at room temperature. After the reaction was complete, the reaction mixture was poured into ethyl acetate (150 mL) and washed with saturated brine (20 mL × 3). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by silica gel column chromatography to obtain 400 mg of a pale yellow solid product, with a yield of 74.5%. LC-MS (ESI, pos.ion) m / z: 433.2 [M+H] + .

[0241] Step 8: Synthesis of 6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]

[0242] A solution of tert-butyl 6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylate (400 mg, 0.96 mmol) in dichloromethane (30 mL) was reacted with 5 mL of trifluoroacetic acid at room temperature. After the reaction was complete, the solution was concentrated under reduced pressure to remove a large amount of trifluoroacetic acid. The reaction solution was then poured into a sodium bicarbonate solution (100 mL) and extracted with dichloromethane (100 mL × 3). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent, yielding 252 mg of a pale yellow solid product, with a yield of 82.1%. LC-MS (ESI, pos.ion) m / z: 333.2 [M+H] + .

[0243] Step 9: 1-(4-amino-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carbonyl)-6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0244] N,N-diisopropylethylamine (160 mg, 1.24 mmol) was added to a solution of 4-amino-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-carboxylic acid (100 mg, 0.41 mmol) and HATU (265 mg, 0.54 mmol) in dichloromethane (15 mL) at room temperature. The mixture was stirred at room temperature for 30 minutes, followed by the addition of 6'-((1-cyclobutyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (112.2 mg, 0.34 mmol). After the reaction was complete, the system was concentrated under reduced pressure, and the residue was purified by column chromatography to give 120 mg of a white solid, yield 53%. LC-MS (ESI, pos.ion) m / z: 557.2 [M+H] + .

[0245] Example 2: 1-(4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-formyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-dihydroindole]-2'-one

[0246] The above-mentioned compound was prepared according to the synthesis scheme of Example 1.

[0247] 1 H NMR (400MHz, CDCl3) δ8.51 (d, J = 7.1Hz, 1H), 7.99 (s, 1H), 7.66 (s, 1H), 7.63 (s,1H),7.56(d,J=7.7Hz,1H),7.40(d,J=12.1Hz,1H),7.30(d,J=7.8Hz,1H) ,6.94(s,1H),5.70(s,2H),4.62(dd,J=51.6,9.2Hz,2H),4.48(s,3H),4.39 (dd,J=24.3,9.7Hz,2H),3.68–3.53(m,1H),3.22(s,3H),1.25–0.87(m,4H).

[0248] ESI-HRMS:calcd.for C 31 H 25 FN8O2,[M+H] + :561.2157,found:561.2168.

[0249] Example 3: 1-(4-amino-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-formyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-dihydroindole]-2'-one

[0250] The above-mentioned compound was prepared according to the synthesis scheme of Example 1.

[0251] 1 H NMR (400MHz, CDCl3) δ8.65 (s, 1H), 8.00 (s, 1H), 7.80 (d, J = 8.7Hz, 1H), 7.71 (d,J=8.7Hz,1H),7.65(s,1H),7.63(s,1H),7.53(d,J=7.6Hz,1H),7.27(d,J =9.5Hz,1H),6.95(s,1H),5.67(s,2H),4.76(d,J=68.0Hz,2H),4.48(s,3H) ,4.46(d,J=16.0Hz,2H),3.65–3.57(m,1H),3.24(s,3H),1.16–1.02(m,4H).

[0252] ESI-HRMS:calcd.for C 31 H 26 N8O2,[M+H] + :543.2251,found:543.2268.

[0253] Example 4: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0254] Step 1: Synthesis of 4-((3-bromo-4-fluorophenyl)ethynyl)-1-cyclopropyl-1H-pyrazole

[0255] 1-Cyclopropyl-4-ethynyl-1H-pyrazole (1.5 g, 11.35 mmol), 2-bromo-1-fluoro-4-iodobenzene (4.10 g, 13.62 mmol), cuprous iodide (0.11 g, 0.57 mmol), palladium dichloride (0.4 g, 0.57 mmol), tetrahydrofuran (30 mL), and triethylamine (2.87 g, 28.38 mmol) were added sequentially to a 100 mL single-necked flask. The reaction was carried out at room temperature under nitrogen protection. After the reaction was complete, 500 mL of ethyl acetate was added to the reaction solution, followed by washing with saturated brine (30 mL × 3 times). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (elution: PE / EtOAc (v / v) = 15 / 1) to give 2.75 g of yellow solid product, yield 79.40%. LC-MS(ESI,pos.ion)m / z:305.0[M+H] + .

[0256] Step 2: Synthesis of 3-[2-bromo-4-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)phenyl]-3-cyanoazacyclobutane-1-carboxylic acid tert-butyl ester

[0257] 4-((3-bromo-4-fluorophenyl)ethynyl)-1-cyclopropyl-1H-pyrazole (2.55 g, 8.36 mmol), tetrahydrofuran (33 mL), and 1-Boc-3-cyanozazenebutane (2.29 g, 12.54 mmol) were added sequentially to a 100 mL two-necked flask. The mixture was cooled to -10 °C under nitrogen protection and stirred for 10 minutes. Then, bis(trimethylsilyl)amino potassium (16.72 mL, 1.0 M) was slowly added dropwise, and the reaction was continued at -10 °C. After the reaction was complete, ethyl acetate (600 mL) was added to the system, and the mixture was washed with saturated brine (50 mL × 4 times). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 12 / 1) to give 137.6 mg of a colorless oily product, with a yield of 3.52%. LC-MS(ESI,pos.ion)m / z:467.1[M+H] + .

[0258] Step 3: Synthesis of 3-[2-bromo-4-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)phenyl]-3-carbamoylazacyclobutane-1-carboxylic acid tert-butyl ester

[0259] 3-[2-bromo-4-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)phenyl]-3-cyanoazacyclobutane-1-carboxylic acid tert-butyl ester (107.6 mg, 0.23 mmol), potassium carbonate (79.47 mg, 0.58 mmol), dimethyl sulfoxide (3.0 mL), water (1.0 mL), and hydrogen peroxide (65.19 mg, 0.58 mmol) were added sequentially to a 25 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was completed, the resulting mixture was diluted with water (100 mL), and then extracted with ethyl acetate (10 mL × 3). The combined organic phases were washed with saturated brine (60 mL × 2 times). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (elution: PE / EtOAc (v / v) = 1 / 1.5) to give 62.1 mg of white solid product, yield 55.57%. LC-MS(ESI,pos.ion)m / z:485.1[M+H] + .

[0260] Step 4: Synthesis of 6'-(1-cyclopropyl-1H-pyrazole-4-ylethynyl)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester

[0261] 3-[2-bromo-4-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)phenyl]-3-carbamoylazacyclobutane-1-carboxylic acid tert-butyl ester (62.1 mg, 0.13 mmol), sodium tert-butoxide (37.48 g, 0.39 mmol), cuprous oxide (4.65 mg, 0.033 mmol), o-phenylenediamine (7.03 mg, 0.065 mmol), and tert-butanol (3 mL) were added sequentially to a 25 mL single-necked flask. The reaction was carried out at 100 °C under nitrogen protection. After the reaction was completed, the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (eluting solvent: PE / EtOAc (v / v) = 1.5 / 1) to give 49.4 mg of a pale yellow solid product, with a yield of 95.3%. LC-MS (ESI, pos.ion) m / z: 405.2 [M+H] + .

[0262] Step 5: Synthesis of 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester

[0263] Add 6'-(1-cyclopropyl-1H-pyrazole-4-ylethynyl)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester (49.4 mg, 0.12 mmol) and tetrahydrofuran (2 mL) to a 10 mL two-necked flask, protect with nitrogen and cool to 0 °C, add sodium hydride (10.0 mg, 0.15 mmol) and continue stirring for 10 minutes, then add iodomethane (25.5 mg, 0.18 mmol) and continue the reaction at room temperature. After the reaction was complete, the system was poured into water (100 mL), and then extracted with ethyl acetate (50 mL × 2 times). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 3 / 1) to give 49.5 mg of white solid product, yield 96.8%. LC-MS (ESI, pos.ion) m / z: 419.2 [M+H] + .

[0264] Step 6: Synthesis of 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-dihydroindole]-2'-one

[0265] 6'-(1-cyclopropyl-1H-pyrazole-4-ylethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester (49.5 mg, 0.12 mmol), dichloromethane (2 mL), and trifluoroacetic acid (136.8 mg, 1.2 mmol) were added sequentially to a 10 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was completed, the solvent, a large amount of trifluoroacetic acid, was removed by concentration under reduced pressure. The pH was then adjusted to 7-8 with 1 M potassium carbonate aqueous solution, and the resulting mixture was diluted with water (50 mL). The mixture was then extracted with ethyl acetate (10 mL × 3), the organic phases were combined, and the mixture was washed with saturated brine (30 mL × 1). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (eluting agent: DCM / MeOH (v / v) = 20 / 1) to give 33.1 mg of white solid product, yield 87.9%. LC-MS(ESI,pos.ion)m / z:319.2[M+H] + .

[0266] Step 7: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-[(1-cyclopropyl-1H-pyrazol-4-yl)ethynyl]-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0267] 4-Amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carboxylic acid (35.5 mg, 0.11 mmol, synthesized according to Example 164 of WO2025036472A1), HATU (81.6 mg, 0.21 mmol), dichloromethane (4 mL), and N,N-diisopropylethylamine (46 mg, 0.36 mmol) were added sequentially to a 10 mL single-necked flask. After reacting at room temperature for 0.5 hours, 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-dihydroindole]-2'-one (35 mg, 0.14 mmol) was added, and the reaction was continued at room temperature. After the reaction was complete, ethyl acetate (200 mL) was added to the system, and the mixture was washed with saturated brine (30 mL × 3 times). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 24 / 1) to give 45 mg of a white solid product, with a yield of 74.8%. LC-MS (ESI, pos.ion) m / z: 549.2 [M+H] + .

[0268] 1 H NMR (400MHz, CDCl3) δ7.84 (d, J = 7.4Hz, 1H), 7.66 (s, 1H), 7.63 (s, 1H), 7.54 (d, J=7.6Hz,1H),7.39(d,J=12.1Hz,1H),7.29(d,J=7.7Hz,1H),6.94(s,1H),5.47 (t,J=3.3Hz,2H),5.15(t,J=3.1Hz,2H),4.88(s,2H),4.58(dd,J=61.6,9.1Hz, 2H), 4.35 (d, J = 9.3Hz, 2H), 3.63–3.58 (m, 1H), 3.21 (s, 3H), 1.16–1.03 (m, 4H).

[0269] Example 5: 1-(4-amino-7-chloro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0270] The above-mentioned compound was prepared according to the synthesis scheme of Example 4.

[0271] 1H NMR(400MHz, CDCl3)δ7.79(s,1H),7.66(s,1H),7.63(s,1H),7.59(s,1H),7 .53(d,J=7.7Hz,1H),7.28(d,J=7.8Hz,1H),6.93(s,1H),5.45(t,J=2.9Hz, 2H),5.15(t,J=3.3Hz,2H),4.84(s,2H),4.51(dd,J=99.8,9.7Hz,2H),4.26 (dd,J=67.7,8.6Hz,2H),3.64–3.58(m,1H),3.21(s,3H),1.16–1.03(m,4H).

[0272] Example 6: 1-(4-amino-7-fluoroimidozop[1,5-a]quinoxaline-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0273] Step 1: Synthesis of 6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1-(4-((2,4-dimethoxybenzyl)amino)-7-fluoroimidozono[1,5-a]quinoxaline-8-formyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0274] Add 4-((2,4-dimethoxybenzyl)amino)-7-fluoroimidazolo[1,5-a]quinoxaline-8-carboxylic acid (126.84 mg, 0.32 mmol, synthesized according to Example 16 of WO2024032572A1), DCM (10 mL), HATU (121.67 mg, 0.32 mmol), and DIPEA (156.4 mg, 1.21 mmol) to a 50 mL single-necked flask and stir at room temperature for 1 h. Then add 6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (50 mg, 0.16 mmol) to the reaction system and continue stirring. After the reaction was complete, an appropriate amount of silica gel was added to the reaction solution, the mixture was concentrated under reduced pressure, and then purified by column chromatography (dichloromethane / methanol (V / V) = 100 / 3), yielding 100 mg of a yellow solid, with a yield of 91.39%. LC-MS (ESI, pos.ion) m / z: 697.2 [M+H] + .

[0275] Step 2: Synthesis of 1-(4-amino-7-fluoroimidozopo[1,5-a]quinoxaline-8-formyl)-6'-[(1-cyclopropyl-1H-pyrazol-4-yl)ethynyl]-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0276] Add 6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1-(4-((2,4-dimethoxybenzyl)amino)-7-fluoroimidozono[1,5-a]quinoxaline-8-formyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (134 mg, 0.22 mmol) to a 25 mL single-necked flask, dissolve it in acetonitrile (9 mL), and slowly add 1.5 mL of an aqueous solution of cerium ammonium nitrate (98.68 mg, 0.18 mmol). Then, place the reaction solution at room temperature and stir for 2.5 h. After the reaction was complete, saturated sodium bicarbonate was added to quench the reaction mixture, and the solution was extracted with ethyl acetate (30 mL × 3 times). The organic phases were combined and concentrated under reduced pressure. The residue was purified by column chromatography (dichloromethane:methanol (V / V) = 100:5) to give 60 mg of white solid, yield 57.1%. LC-MS (ESI, pos.ion) m / z: 547.2 [M+H] + .

[0277] 1 H NMR (400MHz, DMSO-d6) δ9.22(s,1H),8.43(d,J=6.7Hz,1H),8.18(s,1H),7.95(s,1H),7.67(dd,J=7.9,5.3Hz,4H),7.24(t,J=9. 5Hz,2H),7.12(s,1H),4.36-4.22(m,4H),3.76(ddd,J=11.2,7.4,3.8Hz,1H),3.14(s,3H),1.10-1.03(m,2H),1.00-0.95(m,2H).

[0278] Example 7: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-1'-methyl-6'-(1-methyl-1H-pyrazol-4-ylethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0279] The above compound was prepared by referring to the synthesis scheme of Example 4 (replacing the starting material 1-cyclopropyl-4-ethynyl-1H-pyrazole with 1-methyl-4-ethynyl-1H-pyrazole).

[0280] 1H NMR (400MHz, DMSO-d6) δ8.07(s,1H),7.78(d,J=7.8Hz,1H),7.68(d,J=6.7Hz,2H),7.31(d,J=12.5Hz,1H),7.25(d,J=7 .8Hz,1H),7.13(s,1H),6.96(s,2H),5.36(d,J=2.1Hz,2H),5.00(s,2H),4.33–4.21(m,4H),3.86(s,3H),3.14(s,3H).

[0281] Example 8: 1-(4-amino-1-methyl-1,8-dihydropyrazolo[3,4-d]pyrrolo[3,2-b]pyridin-7-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0282] Step 1: Synthesis of tert-butyl (tert-butyloxycarbonyl) (7-(6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carbonyl)-1-methyl-1,8-dihydropyrazolo[3,4-d]pyrrolo[3,2-b]pyridin-4-yl)carbamate

[0283] 4-(bis(tert-butoxycarbonyl)amino)-1-methyl-1,8-dihydropyrazolo[3,4-d]pyrrolo[3,2-b]pyridine-7-carboxylic acid (138.06 mg, 0.32 mmol, obtained by referring to the synthesis method of compound 6A in WO2025077856 A1) and HATU (91.26 mg, 0.24 mmol) were added to a 100 mL single-necked flask, dissolved in dichloromethane (8 mL), and then DIPEA (0.04 mL, 0.24 mmol) was added. The mixture was reacted at room temperature for 1 h. Subsequently, 6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (50 mg, 0.16 mmol) was added to the reaction mixture, and the mixture was stirred at room temperature overnight. After the reaction was completed, the reaction solution was concentrated under reduced pressure to remove the solvent. The residue was purified by column chromatography (DCM / MeOH (V / V) = 50 / 1) to give 112 mg of a yellow solid product, yield 97.45%. LC-MS (ESI, pos.ion) m / z: 732.3 [M+H] + .

[0284] Step 2: Synthesis of 1-(4-amino-1-methyl-1,8-dihydropyrazolo[3,4-d]pyrrolo[3,2-b]pyridin-7-formyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0285] 112 mg, 0.15 mmol of tert-butyl(tert-butyloxycarbonyl)(7-(6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carbonyl)-1-methyl-1,8-dihydropyrazolo[3,4-d]pyrrolo[3,2-b]pyridin-4-yl)carbamate was added to the reaction vessel, dissolved in dichloromethane (2 mL), and TFA (2 mL) was slowly added dropwise to the reaction mixture. The mixture was then placed at room temperature for 1.5 h. After the reaction was complete, saturated sodium bicarbonate solution was added to the reaction solution to adjust the pH to approximately 7. The mixture was then extracted with dichloromethane (10 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH (V / V) = 20 / 1) to give 45.2 mg of a white solid product. Yield: 55.56%. LC-MS (ESI, pos.ion) m / z: 532.2 [M+H] + .

[0286] 1 H NMR (400MHz, DMSO-d6) δ12.35(s,1H),8.39(s,1H),8.18(s,1H),7.76(d,J=7.7Hz,1H),7.69(s,1H),7.53(s,2H),7.25(d,J=7.6 Hz,1H),7.15(s,1H),6.76(s,1H),4.72(d,J=32.3Hz,2H),4.50–4.11(m,5H),3.81–3.72(m,1H),3.17(s,3H),1.10–0.95(m,4H).

[0287] Example 9: 1-(4-amino-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0288] The above-mentioned compound was prepared according to the synthesis scheme of Example 4.

[0289] LC-MS(ESI,pos.ion)m / z:531.2[M+H] + .

[0290] 1 H NMR (400MHz, CDCl3) δ7.96 (d, J=1.9Hz, 1H), 7.88 (dd, J=8.7, 2.0Hz, 1H), 7.78 (d, J= 8.7Hz,1H),7.68(s,1H),7.65(s,1H),7.53(d,J=7.7Hz,1H),7.30(d,J=7.8Hz,1H), 6.96(s,1H),5.51(t,J=3.4Hz,2H),5.20(t,J=3.4Hz,2H),4.99–4.92(m,2H),4.82– 4.64(m,2H),3.66–3.61(m,1H),3.26(s,3H),1.17–1.15(m,2H),1.09–1.07(m,2H).

[0291] Example 10: 1-(4-amino-1-methyl-1H-pyrazolo[4,3-c][1,8]naphthidium-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0292] The above compound was prepared according to the synthetic scheme of Example 4 (the synthetic scheme of intermediate 4-amino-1-methyl-1H-pyrazolo[4,3-c][1,8]naphthidine-8-carboxylic acid was obtained by referring to the method of Example SLG-18 in CN119176814).

[0293] LC-MS(ESI,pos.ion)m / z:544.2[M+H] + .

[0294] 1 H NMR(400MHz, CDCl3) δ9.08(d,J=2.3Hz,1H),8.99(d,J=2.3Hz,1H),8.05(s, 1H),7.68(s,1H),7.66(s,1H),7.58(d,J=7.7Hz,1H),7.27(s,1H),6.99(s,1 H),5.72(s,2H),4.97(s,1H),4.76(s,1H),4.63(s,1H),4.52(s,3H),4.46(s ,1H),3.65–3.62(m,1H),3.27(s,3H),1.17–1.15(m,2H),1.10–1.07(m,2H).

[0295] Example 11: 1-(4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-formyl)-1'-methyl-6'-(3-morpholinylprop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0296] The above compound was prepared according to the synthetic scheme of Example 4 (using 4-propynyl-1-morpholine as the starting material).

[0297] LC-MS(ESI,pos.ion)m / z:554.2[M+H] + .

[0298] 1 H NMR (400MHz, CDCl3) δ8.50(d,J=7.1Hz,1H),8.01(s,1H),7.54(d,J=7.6Hz,1H),7.41(d,J=12.0Hz,1H),7.27(d,J=6.8Hz,1H),6.90(s,1H),6.05 (s,2H),4.61(dd,J=51.9,9.1Hz,2H),4.47(s,3H),4.38(dd,J=25.3,9.1 Hz,2H),3.87–3.73(m,4H),3.53(s,2H),3.21(s,3H),2.69–2.60(m,4H).

[0299] Example 12: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-1'-methyl-6'-(3-morpholinylprop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0300] The above compound was prepared according to the synthetic scheme of Example 4 (using 4-propynyl-1-morpholine as the starting material).

[0301] LC-MS(ESI,pos.ion)m / z:542.1[M+H] + .

[0302] 1H NMR (400MHz, CDCl3) δ7.83(d,J=7.4Hz,1H),7.51(d,J=7.6Hz,1H),7.38(d,J=12.1Hz,1H),7.25(d,J=5.0Hz,1H),6.89(s,1H),5.46(t,J=3.2Hz,2H),5 .14(t,J=3.1Hz,2H),5.14(s,2H),4.57(dd,J=59.9,9.2Hz,2H),4.33(d,J= 9.4Hz,2H),3.89–3.71(m,4H),3.52(s,2H),3.20(s,3H),2.75–2.55(m,4H).

[0303] Example 13: 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-(1-(oxecyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0304] The above compound was prepared using 4-ethynyl-1-(oxecyclobutane-3-yl)-1H-pyrazole (synthesized according to the method in Example 4 of WO2021004421 A1) and 2-bromo-1-fluoro-4-iodobenzene as starting materials, following the synthesis scheme of Example 4.

[0305] LC-MS(ESI,pos.ion)m / z:565.2[M+H] + .

[0306] 1 H NMR (400MHz, CDCl3) δ7.86 (d, J = 7.4Hz, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.57 ( d,J=7.6Hz,1H),7.41(d,J=12.1Hz,1H),7.33(d,J=8.2Hz,1H),6.97(s,1H), 5.50–5.7(m,3H),5.17(t,J=3.4Hz,2H),5.12–5.06(m,4H),4.92(s,2H),4.6 8(d,J=9.8Hz,1H),4.53(d,J=8.7Hz,1H),4.38(d,J=9.3Hz,2H),3.24(s,3H).

[0307] Example 14: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-1'-cyclopropyl-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0308] Referring to the synthesis scheme of Example 4, in the fifth step, iodomethane was replaced with iodocyclopropane to prepare the above-mentioned compound.

[0309] LC-MS(ESI,pos.ion)m / z:575.2[M+H] + .

[0310] 1 H NMR (400MHz, DMSO-d6) δ8.19(s,1H),7.77(d,J=7.8Hz,1H),7.70(s,1H),7.67(d,J=7. 6Hz,1H),7.30(d,J=12.6Hz,1H),7.27–7.23(m,1H),7.15–7.10(m,1H),6.92(s,2H),5. 37(dd,J=6.3,3.4Hz,2H),5.00(t,J=3.4Hz,2H),4.33–4.18(m,4H),3.76(dq,J=11.2,3 .8Hz,1H),2.70–2.63(m,1H),1.09–1.04(m,2H),1.03–0.95(m,4H),0.83–0.79(m,2H).

[0311] Example 15: 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-isopropylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0312] Referring to the synthesis scheme of Example 4, in the fifth step, iodomethane was replaced with 2-iodopropane to prepare the above compound.

[0313] LC-MS(ESI,pos.ion)m / z:577.2[M+H] + .

[0314] 1H NMR (400MHz, DMSO) δ8.17(s,1H),7.77(d,J=7.5Hz,1H),7.69(d,J=6.7Hz,2H),7.30(d,J=12.6Hz,1H),7.26–7.18(m,2H),6.91( s,2H),5.37(s,2H),5.00(s,2H),4.57–4.43(m,1H),4.33–4.22(m,4H),3.76(br,1H),1.39(d,J=6.2Hz,6H),1.22–0.95(m,4H).

[0315] Example 16: 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-(oxetane-3-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0316] Referring to the synthesis scheme of Example 4, in the fifth step, iodomethane was replaced with 3-iodooxyhexacyclobutane to prepare the above compound.

[0317] LC-MS(ESI,pos.ion)m / z:591.2[M+H] + .

[0318] 1 H NMR (400MHz, CDCl3) δ7.86(d,J=7.3Hz,1H),7.71–7.68(m,3H),7.63(d,J=7.6Hz,1H),7.42(d,J=12.1Hz,1H),7.38(d,J=8.6Hz 1H),5.64–5.57(m,1H),5.48(t,J=3.4Hz,2H),5.18–5.05(m,8H),4.65(d,J=9.9Hz,1H),4.51 (d,J=8.7Hz,1H),4.39–4.36(m,2H),3.67-3.61(m,1H),1.18–1.14(m,2H),1.10–1.07(m,2H).

[0319] Example 17: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-6'-((1-(difluoromethyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0320] The above compound was prepared using 1-(difluoromethyl)-4-ethynyl-1H-pyrazole (synthesized according to the method of Example 100 in WO2012123745 A1) and 2-bromo-1-fluoro-4-iodobenzene as starting materials, following the synthesis scheme of Example 4.

[0321] LC-MS(ESI,pos.ion)m / z:559.2[M+H] + .

[0322] 1 H NMR (400MHz, CDCl3) δ8.02(s,1H),7.87(d,J=7.1Hz,1H),7.80(s,1H),7.57(d,J=7.6Hz,1H),7.53(d,J=9.5Hz,1H),7.34(d,J=2.5Hz,1H),7.19(t ,J=60.0Hz,1H),6.97(s,1H),5.48(s,2H),5.17(s,2H),4.66(d,J=9.8Hz ,1H),4.48(d,J=8.6Hz,1H),4.39–4.32(m,2H),3.65(s,2H),3.23(s,3H).

[0323] Example 18: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-((1-methyl-6-oxo-1,6-dihydropyrazin-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0324] The above compound was prepared using 5-iodadiazine-3(2H)-one as the starting material, following the synthesis scheme of Example 4.

[0325] 1 H NMR(400MHz, DMSO-d6)δ7.80-7.75(m,2H),7.62(d,J=9.6Hz,1H),7.39(d,J=7.7Hz,1H),7.32–7.27(m,2H), 7.01(d,J=9.5Hz,1H),6.93(s,2H),5.37(s,2H),5.00(s,2H),4.34-4.24(m,4H),3.69(s,3H),3.16(s,3H).

[0326] Example 19: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-acyl)-6'-((1-(2-methoxyethyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0327] The above compound was prepared using 4-iodo-1-(2-methoxyethyl)-1H-pyrazole as the starting material, following the synthetic protocol described in Example 4. LC-MS (ESI, pos.ion) m / z: 566.8 [M+H] + .

[0328] 1 H NMR (400MHz, CDCl3) δ7.87(d,J=7.3Hz,1H),7.73(s,1H),7.70(s,1H),7.56(d,J=7.7Hz ,1H),7.42(d,J=12.0Hz,1H),7.32(d,J=6.6Hz,1H),6.97(s,1H),5.49(t,J=3.3Hz,2H), 5.18(t,J=3.4Hz,2H),5.05(s,2H),4.68(d,J=9.8Hz,1H),4.52(d,J=8.7Hz,1H),4.37( d,J=9.4Hz,2H),4.32(t,J=5.1Hz,2H),3.77(t,J=5.1Hz,2H),3.37(s,3H),3.24(s,3H).

[0329] Example 20: 6'-((1H-pyrazol-4-yl)ethynyl)-1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0330] The above compound was prepared using 4-iodopyrazole as the starting material, following the synthetic protocol described in Example 4. LC-MS (ESI, pos.ion) m / z: 509.2 [M+H] + .

[0331] 1H NMR (400MHz, DMSO-d6) δ13.21(s,1H),7.78(d,J=7.8Hz,1H),7.68(d,J=7.6Hz,1H),7.31(d,J=12.5Hz,1H),7.26( d,J=8.6Hz,1H),7.14(s,1H),6.95(s,2H),5.42–5.24(m,2H),5.11–4.87(m,2H),4.47–4.04(m,4H),3.14(s,3H).

[0332] Example 21: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-(oxetane-3-ylethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0333] The above compound was prepared using 3-ethynyloxetane as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 499.1 [M+H] + .

[0334] 1 H NMR (400MHz, CDCl3) δ7.84(d,J=7.3Hz,1H),7.54(d,J=7.7Hz,1H),7.42(d, J=11.7Hz,1H),7.26(d,J=6.7Hz,1H),6.91(s,1H),5.45(s,1H),5.15(s,1H) ,4.91(dd,J=8.5,5.5Hz,2H),4.83(t,J=6.4Hz,2H),4.66(d,J=9.8Hz,1H),4 .51(d,J=8.8Hz,1H),4.36(d,J=9.3Hz,2H),4.16-4.08(m,3H),3.22(s,3H).

[0335] Example 22: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-1'-methyl-6'-(prop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0336] The above compound was prepared from 1-(trimethylsilyl)propyne as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 457.2 [M+H] + .

[0337] 1H NMR (400MHz, CDCl3) δ7.83(d,J=7.4Hz,1H),7.49(d,J=7.6Hz,1H),7.39(d,J=12.1Hz,1H),7.20(d,J=6.6Hz,1H),6.86(s,1H),5.46 (t,J=3.3Hz,2H),5.15(t,J=3.2Hz,2H),4.92(s,2H),4.56(dd,J=61.6,9.2Hz,2H),4.33(d,J=9.2Hz,2H),3.19(s,3H),2.07(s,3H).

[0338] Example 23: 1-(4-amino-7-fluoro-1-methyl-1H-pyrazolo[4,3-c]quinoline-8-formyl)-1'-methyl-6'-(prop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0339] The above compound was prepared using 1-(trimethylsilyl)propyne as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 469.2 [M+H] + .

[0340] 1 H NMR (400MHz, CDCl3) δ8.53(d,J=7.2Hz,1H),7.97(s,1H),7.52(d,J=7.7Hz,1H),7.42(d,J=12.2Hz,1H),7.22(d,J=7.5Hz,1H) ,6.87(s,1H),5.42(s,2H),4.60(dd,J=55.2,9.2Hz,2H),4.50(s,3H),4.38(dd,J=22.0,9.2Hz,2H),3.19(s,3H),2.07(s,3H).

[0341] Example 24: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-(3-(piperidin-1-yl)prop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0342] The above compound was prepared using 4-(1,1-dimethyl-2-propynyl)-morpholine as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 570.2 [M+H] + .

[0343] 1 H NMR (400MHz, CDCl3) δ7.85(d,J=7.4Hz,1H),7.53(d,J=7.7Hz,1H),7.39(d,J=12.1Hz,1H),7.28–7.25(m,1H),6.89(s,1H),5.48(t,J=3.4Hz,2H), 5.17(t,J=3.4Hz,2H),4.95(s,2H),4.68–4.52(m,2H),4.37–4.34(m,2H) ,3.80(t,J=4.7Hz,4H),3.23(s,3H),2.74(t,J=4.8Hz,4H),1.49(s,6H).

[0344] Example 25: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-(3-(4-methylpiperazin-1-yl)prop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0345] The above compound was prepared using 1-methyl-4-propynyl-2-piperazine as the starting material, following the synthetic protocol of Example 4. LC-MS (ESI, pos.ion) m / z: 278.15 [M / 2+H] + .

[0346] 1 H NMR (400MHz, CDCl3) δ7.84(d,J=7.4Hz,1H),7.50(d,J=7.6Hz,1H),7.39(d,J=12.1Hz,1H), 7.00–6.96(m,1H),6.92(s,1H),5.47(t,J=3.4Hz,2H),5.15(t,J=3.2Hz,2H),4.99(d,J=15. 9Hz,1H),4.92(d,J=10.0Hz,1H),4.64(d,J=9.8Hz,1H),4.48(d,J=8.8Hz,1H),4.33(d,J=9 .3Hz,2H),3.55(s,2H),3.20(s,3H),2.89–2.69(m,6H),2.59(t,J=8.1Hz,2H),2.37(s,3H).

[0347] Example 26: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-(3-(piperidin-1-yl)prop-1-yn-1-yl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0348] The above compound was prepared using 1-propynepiperidine as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 540.2 [M+H] + .

[0349] 1 H NMR (400MHz, CDCl3) δ7.85(d,J=7.4Hz,1H),7.53(d,J=7.6Hz,1H),7.40(d, J=12.2Hz,1H),7.27(s,1H),6.92(s,1H),5.48(t,J=3.4Hz,2H),5.17(t,J= 3.4Hz,2H),4.98(s,2H),4.66(d,J=9.8Hz,1H),4.52(d,J=8.6Hz,1H),4.35 (d,J=9.3Hz,2H),3.50(s,2H),3.22(s,3H),2.60(s,4H),1.71-1.65(m,6H).

[0350] Example 27: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-((5-methyl-1-(oxecyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0351] The above compound was prepared using 4-ethynyl-5-methyl-1-(oxetane-3-yl)-1H-pyrazole as the starting material, following the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 579.2 [M+H] + .

[0352] 1H NMR (400MHz, CDCl3) δ7.85(d,J=7.3Hz,1H),7.72(s,1H),7.54(d,J=7.6Hz,1H),7.42(d, J=11.9Hz,1H),7.30(d,J=7.8Hz,1H),6.94(s,1H),5.47(s,2H),5.40(dd,J=7.6,5.2Hz, 2H),5.38–5.32(m,1H),5.20(t,J=6.4Hz,2H),5.16(s,2H),5.00(t,J=7.0Hz,2H),4.65( d,J=9.3Hz,1H),4.49(d,J=8.4Hz,1H),4.35(d,J=9.3Hz,2H),3.22(s,3H),2.37(s,3H).

[0353] The synthetic scheme for 4-ethynyl-5-methyl-1-(oxetane-3-yl)-1H-pyrazole is as follows:

[0354] Step 1) Synthesis of 4-iodo-1-(oxetane-3-yl)-1H-pyrazole

[0355] At 0 °C, 4-iodo-1H-pyrazole (0.8 g, 4.12 mmol) was added to a 50 mL single-necked flask and dissolved in DMF (15 mL). Sodium hydride (0.30 g, 12.36 mmol) was then added, and the mixture was stirred for 20 min. 3-iodooxetane (0.83 g, 4.53 mmol) was then added. The reaction mixture was then stirred at 60 °C for 6 h. After the reaction was complete, 30 mL of ammonium chloride aqueous solution was added to quench the reaction, followed by extraction with ethyl acetate (30 mL × 3 times). The organic phases were combined, dried, concentrated, and purified by column chromatography (PE / EtOAc (v / v) = 10 / 1) to obtain a yellow oil (0.8 g, yield 77.58%). LC-MS (ESI, pos.ion) m / z: 251.2 [M+H] + .

[0356] Step 2) Synthesis of 4-iodo-5-methyl-1-(oxetane-3-yl)-1H-pyrazole

[0357] 4-Iodo-1-(oxetane-3-yl)-1H-pyrazole (750 mg, 3.00 mmol) was added to a 100 mL two-necked flask and dissolved in THF (20 mL). The reaction solution was stirred at -78 °C for 30 min, followed by the addition of 2 M LDA (3 mL, 6 mmol) and stirring for 5 h. Iodomethane (0.47 g, 3.30 mmol) was then added, and the reaction solution was stirred at room temperature for 10 h. After the reaction was complete, ammonium chloride solution (30 mL) was added to quench the reaction, followed by extraction with ethyl acetate (30 mL × 3 times). The organic phases were combined, dried, concentrated, and purified by column chromatography (PE / EtOAc (v / v) = 100 / 15) to obtain a white solid (300 mg, yield 37.88%). LC-MS (ESI, pos.ion) m / z: 265.07 [M+H] + .

[0358] Step 3) Synthesis of 4-ethynyl-5-methyl-1-(oxetane-3-yl)-1H-pyrazole

[0359] Under a nitrogen atmosphere, 4-iodo-5-methyl-1-(oxetane-3-yl)-1H-pyrazole (0.61 g, 2.29 mmol), trimethylsilylacetylene (0.45 g, 4.6 mmol), cuprous iodide (23 mg, 0.12 mmol), TEA (750 mg, 6.8 mmol), and PdCl2(PPh3)2 (140 mg, 0.2 mmol) were added to a 50 mL single-necked flask and dissolved in THF (30 mL). The reaction solution was then stirred at room temperature for 12 h. Potassium carbonate (635 mg, 4.6 mmol) was added and the reaction was continued for 3 h. After the reaction was completed, an appropriate amount of silica gel powder was added, and column chromatography was performed for purification (eluent: DCM / MeOH (v / v) = 100 / 1) to obtain a brown oily substance (281 mg, yield 75.1%). LC-MS(ESI,pos.ion)m / z:163.1[M+H] + .

[0360] Example 28: (S)-1-(4-amino-3-methyl-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0361] The above-mentioned compound was prepared according to the synthesis scheme of Example 4.

[0362] 1H NMR(400MHz,Chloroform-d)δ7.94(d,J=1.9Hz,1H),7.87(dd,J=8.7,2.0Hz,1H),7.74(d,J=8.8Hz ,1H),7.67(s,1H),7.65(s,1H),7.52(d,J=7.6Hz,1H),7.29(d,J=1.3Hz,1H),6.96(d,J=1.4Hz,1H ),5.52(d,J=18.8Hz,2H),5.39(d,J=18.2Hz,1H),4.95(s,2H),4.73(d,J=59.6Hz,2H),4.45(s,2H ),3.63(d,J=22.1Hz,1H),3.25(s,3H),1.59(d,J=6.0Hz,3H),1.18(s,2H),1.07(d,J=15.9Hz,2H).

[0363] Example 29: 1-(4-amino-1,3-dihydrofurano[3,4-c][1,7]naphthidium-8-carbonyl)-6'-((1-cyclopropyl-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0364] The above-mentioned compound was prepared according to the synthesis scheme of Example 4.

[0365] 1 H NMR (400MHz, CDCl3) δ7.86 (d, J = 7.4Hz, 1H), 7.83 (s, 1H), 7.78 (s, 1H), 7.57 ( d,J=7.6Hz,1H),7.41(d,J=12.1Hz,1H),7.33(d,J=8.2Hz,1H),6.97(s,1H), 5.50–5.7(m,3H),5.17(t,J=3.4Hz,2H),5.12–5.06(m,4H),4.92(s,2H),4.6 8(d,J=9.8Hz,1H),4.53(d,J=8.7Hz,1H),4.38(d,J=9.3Hz,2H),3.24(s,3H).

[0366] Example 30: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-ethynyl-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0367] The above compound was prepared from triisopropylsilylacetylene according to the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 443.1 [M+H] + .

[0368] 1 H NMR (400MHz, CDCl3) δ7.85(d,J=7.3Hz,1H),7.54(d,J=7.5Hz,1H),7.41(d,J=12.3Hz,1H),7.33(d,J=7.6Hz,1H),6.95(s,1 H),5.47(s,2H),5.15(s,2H),4.65(d,J=9.9Hz,1H),4.49(d,J=8.3Hz,1H),4.34(d,J=9.6Hz,2H),3.21(s,3H),3.14(s,1H).

[0369] Example 31: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-1'-methyl-6'-[3-(1-methylpiperidin-4-yl)prop-1-yn-1-yl]spiro[azacyclobutane-3,3'-indoline]-2'-one

[0370] The above compound was prepared from 1-methyl-4-(prop-2-yn-1-yl)piperidine according to the synthetic scheme of Example 4. LC-MS (ESI, pos.ion) m / z: 554.2 [M+H] + .

[0371] 1 H NMR(400MHz, CDCl3) δ7.83(d,J=7.3Hz,1H),7.52–7.47(m,1H),7.39(d,J=12.1Hz,1H),7.21(d,J =7.8Hz,1H),6.98(s,1H),5.46(t,J=3.1Hz,2H),5.16–5.13(m,2H),4.63(d,J=9.7Hz,1H),4.48( d,J=8.6Hz,1H),4.32(d,J=9.4Hz,2H),3.96–3.88(m,1H),3.64(s,3H),3.44(dd,J=18.3,5.5Hz, 2H),3.22(s,3H),2.65–2.55(m,2H),2.48(d,J=6.2Hz,2H),2.35–2.28(m,2H),2.25–2.18(m,2H).

[0372] Example 32: 2-(4-((1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-acyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-6'-yl)ethynyl)-1H-pyrazole-1-yl)acetonitrile

[0373] A solution of compound 20 (60 mg, 0.12 mmol) in DMF (5 mL) was added with bromoacetonitrile (18 mg, 0.15 mmol) and cesium carbonate (78 mg, 0.24 mmol), and the reaction was carried out overnight at room temperature. After the reaction was completed as detected by TLC, the solvent was removed by concentration under reduced pressure, and the residue was separated by column chromatography (DCM / MeOH = 100 / 2) to give 30 mg of white solid product, with a yield of 46.4%. LC-MS (ESI, pos.ion) m / z: 548.2 [M+H] + .

[0374] 1 H NMR (400MHz, CDCl3) δ7.87(d,J=7.3Hz,1H),7.79(s,1H),7.77(s,1H),7.58(d,J=7.6Hz,1H),7.47–7.41(m ,3H),7.33(d,J=7.8Hz,1H),6.98(s,1H),5.50–5.42(m,4H),5.19-5.15(m,4H),5.12(s,2H),3.25(s,3H).

[0375] Example 33: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-acyl)-1'-methyl-6'-((1-(2-morpholinoethyl)-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0376] A solution of compound 20 (60 mg, 0.12 mmol) in DMF (5 mL) was added with 4-(2-bromoethyl)morpholine hydrobromide (42 mg, 0.15 mmol) and cesium carbonate (78 mg, 0.24 mmol), and the reaction was carried out overnight at room temperature. After the reaction was completed as detected by TLC, the solvent was removed by concentration under reduced pressure, and the residue was separated by column chromatography (DCM / MeOH = 100 / 2) to give 18 mg of white solid product, with a yield of 24.6%. LC-MS (ESI, pos.ion) m / z: 622.3 [M+H] + .

[0377] 1H NMR(400MHz,Chloroform-d)δ7.86(d,J=7.3Hz,1H),7.73(s,1H),7.69(s,1H),7.56(d,J=7.7Hz,1 H),7.41(d,J=12.1Hz,1H),7.32(d,J=8.0Hz,1H),6.97(s,1H),5.49(t,J=3.4Hz,2H),5.17(t,J=3 .4Hz,2H),5.02(s,2H),4.68(d,J=9.9Hz,1H),4.52(d,J=8.6Hz,1H),4.37(d,J=9.3Hz,2H),4.27( t,J=6.3Hz,2H),3.73(t,J=4.6Hz,4H),3.24(s,3H),2.84(t,J=6.4Hz,2H),2.51(t,J=4.5Hz,4H).

[0378] Example 34: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-acyl)-6'-((1-(2-hydroxy-2-methylpropyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0379] A solution of compound 20 (102 mg, 0.2 mmol) in acetonitrile (5 mL) was reacted with methylpropane (36 mg, 0.5 mmol) and potassium carbonate (56 mg, 0.5 mmol) at 80 °C. After the reaction was complete as detected by TLC, the solvent was removed by concentration under reduced pressure. The residue was separated by column chromatography (DCM / MeOH = 100 / 2) to give 48 mg of a white solid product, with a yield of 41.2%. LC-MS (ESI, pos.ion) m / z: 581.2 [M+H] + .

[0380] 1H NMR (400MHz, CDCl3) δ7.86 (d, J = 7.3Hz, 1H), 7.74 (s, 1H), 7.68 (s, 1H), 7.57 (d, J=7.6Hz,1H),7.42(d,J=12.0Hz,1H),7.32(d,J=6.3Hz,1H),6.97(s,1H),5.49( t,J=3.4Hz,2H),5.18(t,J=3.4Hz,2H),5.13(s,1H),4.68(d,J=9.8Hz,1H),4.53 (d,J=8.7Hz,1H),4.38(d,J=7.9Hz,2H),4.11(s,2H),3.24(s,3H),1.22(s,6H).

[0381] Example 35: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-6'-((1-(1-methoxy-2-methylpropane-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0382] Step 1) Synthesis of methyl 2-(4-iodo-1H-pyrazol-1-yl)-2-methylpropionate

[0383] Methyl 2-bromo-2-methylpropionate (3.36 g, 18.56 mmol) was added to 2.5 mL of DMF containing 4-iodo-1H-pyrazole (3 g, 15.47 mmol) and cesium carbonate (10.08 g, 30.94 mmol), and the mixture was heated to 80 °C. After the reaction was complete, the system was filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography (PE:EtOAc = 100:20) to give the target product (2.75 g, yield 60.46%) as a colorless liquid. LC-MS (ESI, pos.ion) m / z: 294.8 [M+H] + .

[0384] Step 2) Synthesis of 2-(4-iodo-1H-pyrazol-1-yl)-2-methylprop-1-ol

[0385] Sodium borohydride (0.63 g, 17.68 mmol) was slowly added to 2.6 g (8.84 mmol) of methyl 2-(4-iodo-1H-pyrazol-1-yl)-2-methylpropionate in 30 mL of ethanol, and the mixture was stirred at room temperature. After the reaction was complete, the mixture was poured into 200 mL of ethyl acetate and washed with saturated brine (30 mL × 4). The organic layer was concentrated under reduced pressure and subjected to column chromatography (PE:EtOAc = 100:45) to give the target product (1.85 g, yield 78.64%) as a white solid. LC-MS (ESI, pos.ion) m / z: 266.8 [M+H] + .

[0386] Step 3) Synthesis of 4-iodo-1-(1-methoxy-2-methylpropyl-2-yl)-1H-pyrazole

[0387] Sodium hydride (0.20 g, 4.89 mmol) was slowly added to 15 mL of THF containing 1 g (1 g, 3.76 mmol) of 2-(4-iodo-1H-pyrazol-1-yl)-2-methylprop-1-ol, and the mixture was stirred for 10 minutes. Iodomethane (0.64 g, 4.51 mmol) was then added, and the mixture was stirred at room temperature. After the reaction was complete, the mixture was poured into 150 mL of ethyl acetate and washed with saturated brine (30 mL × 5). The organic layer was then subjected to rotary cyclohexane chromatography (PE:EtOAc = 100:35) to obtain the target product (950 mg, yield 90.24%) as a yellow liquid. LC-MS (ESI, pos.ion) m / z: 281.1 [M+H] + .

[0388] Step 4) Synthesis of 1-(1-methoxy-2-methylpropyl-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-pyrazole

[0389] Triethylsilylacetylene (1.43 g, 7.86 mmol), CuI (0.075 g, 0.39 mmol), DIPEA (1.27 g, 9.83 mmol), and bis(triphenylphosphine)-palladium dichloride (0.14 g, 0.20 mmol) were added to 30 mL of THF containing 1.1 g (3.93 mmol) of 4-iodo-1-(1-methoxy-2-methylpropyl-2-yl)-1H-pyrazole. The reaction was carried out at room temperature under nitrogen protection. After the reaction was completed, the system was concentrated under reduced pressure and subjected to column chromatography (PE:EtOAc = 100:15) to give the target product (1.26 g, yield 95.9%) as a pale yellow liquid.

[0390] Step 5) Synthesis of tert-butyl 6'-((1-(1-methoxy-2-methylprop-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid

[0391] CuI (0.017 g, 0.09 mmol), bis(triphenylphosphine)palladium dichloride (0.047 g, 0.068 mmol), DIPEA (0.17 g, 1.35 mmol) and TBAF (0.18 g, 0.68 mmol, 1 M) were added to 20 mL of THF containing 1-(1-methoxy-2-methylpropyl-2-yl)-4-((triisopropylsilyl)ethynyl)-1H-pyrazole (150 mg, 0.45 mmol) and 6'-iodo-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid tert-butyl ester (0.19 g, 0.45 mmol) and 1 ...8 g, 0.68 mmol, 1 M) and reacted at room temperature under nitrogen protection. After the reaction, the system was concentrated under reduced pressure, and the residue was purified by column chromatography (PE:EtOAc = 100:30) to obtain the target product (100 mg, yield 48%) as a pale yellow solid. LC-MS (ESI, pos.ion) m / z: 465.1 [M+H] + .

[0392] Step 6) Synthesis of 6'-((1-(1-methoxy-2-methylprop-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0393] TFA (0.16 mL, 2.2 mmol) was added to 3 mL of DCM containing 100 mg (0.22 mmol) of 6'-((1-(1-methoxy-2-methylpropyl-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid tert-butyl ester (DCM) and reacted at room temperature. After the reaction was complete, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed with saturated sodium bicarbonate solution (50 mL × 4). The organic layer was concentrated under reduced pressure, and the residue was purified by column chromatography (DCM: MeOH = 0–3%) to give a colorless viscous substance (60 mg, yield 76.48%). LC-MS (ESI, pos.ion) m / z: 365.3 [M+H] + .

[0394] Step 7) Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-acyl)-6'-((1-(1-methoxy-2-methylpropane-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0395] DIPEA (0.074 g, 0.57 mmol) was added to 5 mL of DCM containing 4-amino-7-fluoro-1H,3H-furano[3,4-c]quinoline-8-carboxylic acid (0.071 g, 0.29 mmol) and HATU (0.094 g, 0.25 mmol), and the mixture was stirred at room temperature for 30 minutes. Then, 6'-((1-(1-methoxy-2-methylpropyl-2-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (70 mg, 0.19 mmol) was added, and the mixture was stirred at room temperature. After the reaction was complete, the system was evaporated to dryness and subjected to column chromatography twice (DCM:MeOH = 100:5) to obtain the target product (55 mg, yield 45.39%) as a white solid. LC-MS(ESI,pos.ion)m / z:595.4[M+H] + .

[0396] 1 H NMR (400MHz, DMSO-d6) δ8.16(s,1H),7.98(d,J=7.1Hz,1H),7.73(s,1H),7.70(d,J=7.6Hz,1H),7.54(d,J=11.2Hz,1H),7.26(d,J=7.6Hz,1 H),7.14(s,1H),5.46(d,J=3.6Hz,2H),5.06(t,J=3.7Hz,2H),4.30(p,J=10.1Hz,4H),3.56(s,2H),3.19(s,3H),3.15(s,3H),1.51(s,6H).

[0397] Example 36: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-6'-((1-((1-hydroxycyclobutyl)methyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0398] At 0°C, DEAD (77 mg, 0.44 mmol) was added to a tetrahydrofuran (5 mL) solution of compound 20 (150 mg, 0.29 mmol), 1-(hydroxymethyl)cyclobutane-1-ol (36.5 mg, 0.35 mmol), and triphenylphosphine (116 mg, 0.44 mmol), and the reaction was allowed to proceed to room temperature. After the reaction was completed as detected by TLC, the solvent was removed by concentration under reduced pressure. The residue was separated by column chromatography (DCM / MeOH = 100 / 2) to give 48 mg of a white solid product, with a yield of 27.5%. LC-MS (ESI, pos.ion) m / z: 593.2 [M+H] + .

[0399] Example 37: 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-((3-hydroxyoxetane-3-yl)methyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0400] Step 1: Synthesis of 6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0401] To a 25 mL single-necked flask, tert-butyl 6'-iodo-1'-methyl-2'-oxo-1',2'-dihydrospiro[azacyclobutane-3,3'-indole]-1-carboxylic acid ester (500 mg, 1.21 mmol), dichloromethane (5 mL), and trifluoroacetic acid (1379.64 mg, 12.1 mmol) were added sequentially, and the reaction was carried out at room temperature. After the reaction was completed, the solvent and excess trifluoroacetic acid were removed by concentration under reduced pressure. The pH was adjusted to 8 with 1 M potassium carbonate aqueous solution. The residue was purified by silica gel column chromatography (eluting solvent: DCM / MeOH (v / v) = 8 / 1) to give 375.0 mg of yellow solid product, yield 98.90%. LC-MS (ESI, pos.ion) m / z: 314.9 [M+H] + .

[0402] Step 2: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0403] 4-Amino-7-fluoro-1H,3H-furan[3,4-c]quinoline-8-carboxylic acid (148.93 mg, 0.60 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (355.90 mg, 0.94 mmol), dichloromethane (13 mL), acetonitrile (13 mL), N,N-diisopropylethylamine (201.61 mg, 1.56 mmol) and 6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (150.0 mg, 0.48 mmol) were added sequentially to a 100 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was complete, the pH was adjusted to 7-8 with 1M ammonium chloride aqueous solution to quench the reaction. The organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (100 mL) and then extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (60 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 15 / 1) to give 104.7 mg of white solid product, yield 40.35%. LC-MS (ESI, pos.ion) m / z: 544.8 [M+H] + .

[0404] Step 3: Synthesis of (3-hydroxyoxetane-3-yl)methyl-4-methylbenzenesulfonate

[0405] 3-(hydroxymethyl)oxetane-3-ol (800 mg, 7.68 mmol), dichloromethane (10 mL), acetonitrile (10 mL), triethylamine (1942.85 mg, 19.2 mmol), p-toluenesulfonyl chloride (1830.24 mg, 9.6 mmol) and 4-dimethylaminopyridine (1172.83 mg, 9.6 mmol) were added sequentially to a 50 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was complete, the pH was adjusted to 7 with 1M ammonium chloride aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (200 mL), and then extracted with dichloromethane (30 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluting solvent: PE / EtOAc (v / v) = 2 / 1) to give 409.1 mg of white solid product, with a yield of 20.61%. LC-MS (ESI, pos.ion) m / z: 259.1 [M+H] + .

[0406] Step 4: Synthesis of 3-((4-iodo-1H-pyrazol-1-yl)methyl)oxecyclobutane-3-ol

[0407] 4-Iodopyrazole (300 mg, 1.55 mmol), (3-hydroxyoxetane-3-yl)methyl-4-methylbenzenesulfonate (408.36 mg, 1.58 mmol), cesium carbonate (1262.55 mg, 3.88 mmol), and N,N-dimethylformamide (20 mL) were added sequentially to a 50 mL single-necked flask, and the reaction was carried out at 80 °C. After the reaction was completed, the resulting mixture was diluted with water (100 mL), and then extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluting agent: PE / EtOAc (v / v) = 2 / 1) to give 433.10 mg of a colorless oily product, with a yield of 99.99%. LC-MS(ESI,pos.ion)m / z:28.09[M+H] + .

[0408] Step 5: Synthesis of 3-((4-((trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl)oxetane-3-ol

[0409] 3-((4-iodo-1H-pyrazol-1-yl)methyl)oxecyclobutane-3-ol (433.15 mg, 1.55 mmol), cuprous iodide (29.52 mg, 0.16 mmol), bis(triphenylphosphine)palladium dichloride (108.79 mg, 0.16 mmol), tetrahydrofuran (10 mL), trimethylsilylacetylene (190.30 mg, 1.94 mmol), and triethylamine (392.11 mg, 3.88 mmol) were added sequentially to a 25 mL single-necked flask, and the reaction was carried out at room temperature under nitrogen atmosphere. After the reaction was complete, the pH was adjusted to 6-7 with 1M ammonium chloride aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (100 mL), and then extracted with dichloromethane (15 mL × 3). The organic phases were combined, washed with saturated brine (50 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 2 / 1) to give 230.0 mg of a yellow solid product, with a yield of 59.40%. LC-MS (ESI, pos.ion) m / z: 251.1 [M+H] + .

[0410] Step 6: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-((3-hydroxyoxetane-3-yl)methyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0411] Add 1-(4-amino-7-fluoro-1H,3H-furan[3,4-c]quinoline-8-carbonyl)-6'-iodo-1'-methyl-1',2'-dihydrospiro[azacyclobutane-3,3'-indole]-2'-one (100 mg, 0.18 mmol) and 3-[(4-(2-(trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)methyl]oxetane to a 50 mL single-necked flask. -3-ol (67.60 mg, 0.27 mmol), cuprous iodide (3.43 mg, 0.018 mmol), palladium dichloride of bis(triphenylphosphine) (12.63 mg, 0.018 mmol), N,N-dimethylformamide (10 mL), triethylamine (45.54 mg, 0.45 mmol) and tetrabutylammonium fluoride (94.13 mg, 0.36 mmol), reacted at room temperature under nitrogen atmosphere. After the reaction was complete, the pH was adjusted to 6-7 with 1M ammonium chloride aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (100 mL), and then extracted with ethyl acetate (15 mL × 3). The organic phases were combined, washed with saturated brine (50 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 1 / 1.5) to give 26.8 mg of a pale yellow solid product, with a yield of 24.53%. LC-MS (ESI, pos.ion) m / z: 595.1 [M+H] + .

[0412] 1 H NMR (400MHz, CDCl3) δ7.86(d,J=7.3Hz,1H),7.71(d,J=8.5Hz,2H),7.55(d,J=7.8Hz,1H),7.43(d,J=12.1Hz,1H),7.30(d,J=8 .1Hz,1H),6.95(s,1H),5.47(s,2H),5.16(s,2H),4.71–4.60(m,3H),4.53(s,2H),4.51–4.31(m,5H),3.22(s,3H),2.98(s,2H)

[0413] Example 38: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-6'-((1-(1-hydroxycyclopropyl)methyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0414] At 0°C, DEAD (102.9 mg, 0.59 mmol) was added to an 8 mL solution of compound 20 (200 mg, 0.39 mmol), 1-(hydroxymethyl)cyclopropyl-1-ol (42.5 mg, 0.47 mmol), and triphenylphosphine (156 mg, 0.6 mmol) in tetrahydrofuran, and the reaction was allowed to proceed to room temperature. After the reaction was complete as detected by TLC, the solvent was removed by concentration under reduced pressure. The residue was separated by column chromatography (DCM / MeOH = 100 / 2) to give 18 mg of a white solid product, with a yield of 7.9%. LC-MS (ESI, pos.ion) m / z: 579.2 [M+H] + .

[0415] Example 39: 3-(4-(1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-6'-yl)ethynyl)-1H-pyrazole-1-yl)propionitrile

[0416] To a DMF (6 mL) solution of compound 20 (82 mg, 0.16 mmol), 3-bromopropionitrile (32.2 mg, 0.24 mmol) and cesium carbonate (105.2 mg, 0.32 mmol) were added, and the mixture was heated to 80 °C and reacted overnight. After the reaction was complete as detected by TLC, the mixture was poured into ethyl acetate (100 mL), washed with saturated brine (25 mL × 5), and the organic layer was concentrated under reduced pressure. The residue was separated by column chromatography (DCM / MeOH = 100 / 2) to obtain 25 mg of a white solid product, with a yield of 27.6%. LC-MS (ESI, pos.ion) m / z: 562.3 [M+H] + .

[0417] 1 H NMR (400MHz, DMSO-d6) δ8.20(s,1H),7.80(s,1H),7.78(d,J=7.9Hz,1H),7.69(d,J=7.6Hz,1H),7.36–7.24(m,2H),7.16(s,1H), 6.92(s,2H),5.44–5.30(m,2H),5.06–4.90(m,2H),4.42(t,J=6.3Hz,2H),4.37–4.18(m,4H),3.14(s,3H),3.09(t,J=6.3Hz,2H).

[0418] Example 40: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-6'-((1-(cyclopropylsulfonyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0419] To a mixed solution of compound 20 (40.4 mg, 0.079 mmol) in DCM (3 mL) and ACN (3 mL), TEA (39.97 mg, 0.40 mmol), 4-dimethylaminopyridine (9.65 mg, 0.079 mmol), and cyclopropylsulfonyl chloride (27.77 mg, 0.20 mmol) were added, and the reaction was carried out at 50 °C under nitrogen protection. After the reaction was completed as detected by TLC, the system was concentrated under reduced pressure to remove most of the solvent, and then poured into ethyl acetate (100 mL). The mixture was washed with saturated brine (25 mL × 4), and the organic layer was concentrated under reduced pressure. The residue was separated by column chromatography (DCM / MeOH = 100 / 2) to obtain 20 mg of white solid product, with a yield of 41.1%. LC-MS (ESI, pos.ion) m / z: 612.9 [M+H] + .

[0420] 1 H NMR (599MHz, DMSO-d6) δ8.71(s,1H),8.22(s,1H),7.78(d,J=7.7Hz,1H),7.73(d,J=7.6Hz,1H),7.34–7.26(m,2H),7.18(s,1 H),6.92(s,2H),5.43–5.33(m,2H),5.06–4.94(m,2H),4.37–4.19(m,4H),3.22–3.17(m,1H),3.14(s,3H),1.37–1.27(m,4H).

[0421] Example 41: 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-6'-(1-fluorovinyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0422] Step 1) Synthesis of tert-butyl 3-(2-bromo-4-iodophenyl)-3-cyanoazonicyclobutane-1-carboxylate

[0423] 2-Bromo-4-iodofluorobenzene (24.5 g, 81.43 mmol) and tert-butyl 3-cyanozycyclobutane-1-carboxylic acid (20.03 g, 109.93 mmol) were added to a reaction vessel, dissolved in THF (200 mL), and cooled to -10 °C. Then, sodium bis(trimethylsilylamino)amine (2 M in THF, 61.07 mL, 122.15 mmol) was slowly added to the reaction mixture, and the mixture was stirred at -10 °C for 18 h. After the reaction was complete, a saturated ammonium chloride solution was added to the reaction mixture to quench the reaction. The aqueous phase was then extracted with EtOAc (250 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove excess solvent. The residue was purified by column chromatography (PE / EtOAc (V / V) = 4 / 1) to give a white solid product (12 g, yield 31.82%). LC-MS(ESI,pos.ion)m / z:419.1[M-tBu+H] + .

[0424] Step 2) Synthesis of tert-butyl 3-(2-bromo-4-iodophenyl)-3-carbamoylazine-1-carboxylic acid

[0425] Potassium carbonate (1.02 g, 7.4 mmol) was added to tert-butyl 3-(2-bromo-4-iodophenyl)-3-cyanozylated cyclobutane-1-carboxylate (1.37 g, 2.96 mmol) in a reaction vessel, followed by the addition of DMSO (15 mL), water (5 mL), and THF (5 mL) to dissolve the esters completely. Then, 30% hydrogen peroxide aqueous solution (0.42 mL, 7.4 mmol) was added to the reaction system, and the mixture was stirred at room temperature for 5 h. After the reaction was complete, water (100 mL) was added to the reaction mixture for dilution, followed by extraction of the aqueous phase with EtOAc (100 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove excess solvent. The residue was purified by column chromatography (DCM / MeOH (V / V) = 100 / 3) to give a white solid product (1.30 g, yield 91.34%). LC-MS(ESI,pos.ion)m / z:425.7[M-tBu+H] + .

[0426] Step 3) Synthesis of tert-butyl 6'-iodo-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid

[0427] Under a nitrogen atmosphere, tert-butyl 3-(2-bromo-4-iodophenyl)-3-carbamoylazetane-1-carboxylic acid (1.42 g, 2.95 mmol), cuprous oxide (0.042 g, 0.30 mmol), o-phenylenediamine (0.064 g, 0.59 mmol), and sodium tert-butoxide (0.85 g, 8.85 mmol) were added to a reaction vessel, dissolved in isopropanol (12 mL), and reacted at 80 °C for 16 h. After the reaction was complete, the reaction mixture was filtered through diatomaceous earth to remove insoluble matter, and the filter residue was washed with EtOAc. The filtrate was concentrated under reduced pressure to remove excess solvent, and the residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 50 / 1) to give a yellow solid product (0.824 g, yield 69.76%). LC-MS (ESI, pos.ion) m / z: 344.9 [M-tBu+H] + .

[0428] Step 4) Synthesis of tert-butyl 6'-iodo-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid

[0429] Under a nitrogen atmosphere, tert-butyl 6'-iodo-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid was added to a reaction vessel (500 mg, 1.25 mmol). The solution was dissolved in THF (10 mL) and placed at 0 °C. Sodium hydride (75 mg, 1.88 mmol) was added in portions, and the mixture was stirred at 0 °C for 30 min. Iodomethane (230 mg, 1.63 mmol) was then added to the reaction mixture. After the addition was complete, the mixture was transferred to room temperature and stirred overnight. After the reaction was complete, a saturated ammonium chloride solution was added to quench the reaction mixture. The aqueous phase was then extracted with EtOAc (20 mL × 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove excess solvent. The residue was purified by silica gel column chromatography (PE / EtOAc (V / V) = 4 / 1) to obtain an orange-yellow solid product (311 mg, yield 60.09%). LC-MS(ESI,pos.ion)m / z:359.0[M-tBu+H] + .

[0430] Step 5) Synthesis of tert-butyl 6'-(1-fluorovinyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid

[0431] Under a nitrogen atmosphere, tert-butyl 6'-iodo-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid (100 mg, 0.24 mmol), (1-fluorovinyl)methyldiphenylsilane (87.25 mg, 0.36 mmol), cesium fluoride (91.14 mg, 0.60 mmol), bis(triphenylphosphine)palladium dichloride (16.85 mg, 0.024 mmol), and cuprous iodide (9.14 mg, 0.048 mmol) were added to the reaction vessel, dissolved in DMF (3 mL), and stirred at room temperature for 3 h. After the reaction was complete, ethyl acetate (10 mL) was added to the reaction solution for dilution, followed by washing with saturated brine. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove excess solvent. The residue was purified by silica gel column chromatography (PE / EtOAc (V / V) = 4 / 1) to give a yellow solid product (80 mg, yield 99%). LC-MS (ESI, pos.ion) m / z: 277.0 [M-tBu+H] + .

[0432] Step 6) Synthesis of 6'-(1-fluorovinyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0433] TFA (1 mL) was added to a 4 mL solution of tert-butyl 6'-(1-fluorovinyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid (tert-butyl ester, 0.36 mmol) in dichloromethane, and the mixture was stirred at room temperature for 1 h. After the reaction was complete, the reaction mixture was concentrated under reduced pressure to remove excess solvent, then diluted with an appropriate amount of dichloromethane, and the pH was adjusted to near neutral with saturated sodium bicarbonate solution. The mixture was then extracted with dichloromethane (15 mL × 3), the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to remove excess solvent. The residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 25 / 1) to give a white solid product (55 mg, yield 65.59%). LC-MS (ESI, pos.ion) m / z: 233.0 [M-tBu+H] + .

[0434] Step 7) Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-6'-(1-fluorovinyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0435] 4-Amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carboxylic acid (25.62 mg, 0.10 mmol) and HATU (39.24 mg, 0.10 mmol) were added to the reaction vessel, dissolved in anhydrous DCM (12 mL), and then DIPEA (0.043 mL, 0.26 mmol) was added. The mixture was stirred at room temperature for 1 h. Subsequently, 6'-(1-fluorovinyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (20 mg, 0.086 mmol) was added to the reaction mixture, and the mixture was stirred at room temperature overnight. After the reaction was completed, the reaction mixture was concentrated under reduced pressure to remove excess solvent. The residue was then purified by preparative HPLC (column type: NOVASEP 50 / 80mm DAC; mobile phase: ACN / H2O (+0.1% TFA) = 32% / 68%) to give a white solid product (5 mg, yield 12.56%). LC-MS (ESI, pos.ion) m / z: 463.0 [M+H] + .

[0436] 1 H NMR (400MHz, DMSO-d6) δ7.79(d,J=7.8Hz,1H),7.74(d,J=7.8Hz,1H),7.40(d,J=7.8Hz,1H),7.31(d,J=12.6Hz,1H),7.27 (s,1H),6.93(s,2H),5.50(dd,J=52.3,3.9Hz,1H),5.39–5.31(m,2H),5.04–4.94(m,3H),4.36–4.20(m,4H),3.17(s,3H).

[0437] Example 42: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carbonyl)-6'-((1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0438] Step 1) Synthesis of 4-iodo-1-(5,8-dioxaspiro[3,4]octane-2-yl)-1H-pyrazole

[0439] Adding 2-bromo-5,8-dioxaspiro[3,4]octane (3.88 g, 20.11 mmol) to a DMF mixture of 4-iodopyrazole (3 g, 15.47 mmol) and cesium carbonate (10.08 g, 30.94 mmol) to 80 °C, the reaction mixture was heated to 80 °C. After the reaction was complete, the mixture was poured into ethyl acetate (250 mL) and washed with saturated brine (50 mL × 7). The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc(V / V) = 100 / 20) to obtain the target product (1.57 g, yield 33.16%) as a yellow solid. LC-MS (ESI, pos.ion) m / z: 306.8 [M+H] + .

[0440] Step 2) Synthesis of 3-(4-iodo-1H-pyrazol-1-yl)cyclobutanone

[0441] Add 1 mL of hydrochloric acid (1 M) to 1,4-dioxane (15 mL) of 1-iodo-1-(5,8-dioxaspiro[3,4]octane-2-yl)-1H-pyrazole (1.45 g, 4.74 mmol) and stir at room temperature. After the reaction is complete, pour the mixture into 100 mL of saturated sodium bicarbonate solution and extract with ethyl acetate (100 mL × 3). Concentrate the organic layer under reduced pressure. The residue is purified by silica gel column chromatography (PE / EtOAc (V / V) = 100 / 40) to obtain the target product (0.98 g, yield 78.95%) as a white solid. LC-MS (ESI, pos.ion) m / z: 262.8 [M+H] + .

[0442] Step 3) Synthesis of 3-(4-iodo-1H-pyrazol-1-yl)-1-methylcyclobutane-1-ol

[0443] At 0 °C, methyl magnesium bromide (0.36 g, 3.06 mmol, 3 M) was added to 15 mL of THF containing 400 mg (1.53 mmol) of 3-(4-iodo-1H-pyrazol-1-yl)cyclobutanone, followed by slow heating to room temperature. After the reaction was complete as monitored by TLC, the mixture was poured into 150 mL of ethyl acetate and washed with saturated brine (20 mL × 5). The organic layer was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc (V / V) = 100 / 50) to obtain the target product (300 mg, yield 70.67%) as a colorless liquid. LC-MS (ESI, pos.ion) m / z: 278.8 [M+H] + .

[0444] Step 4) Synthesis of 1-methyl-3-(4-((triisopropylsilyl)ethynyl)-1H-pyrazol-1-yl)cyclobut-1-ol

[0445] Triethylsilylacetylene (0.39 g, 2.16 mmol), cuprous iodide (0.021 g, 0.11 mmol), DIPEA (0.35 g, 2.7 mmol), and palladium dichloride (0.038 g, 0.054 mmol) were added to 30 mL of THF containing 3-(4-iodo-1H-pyrazol-1-yl)-1-methylcyclobutane-1-ol (300 mg, 1.08 mmol). The reaction was carried out at room temperature under nitrogen protection. After the reaction was completed, the system was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (PE / EtOAc (V / V) = 100 / 15) to obtain the target product (100 mg, yield 27.87%) as a pale yellow liquid. LC-MS (ESI, pos.ion) m / z: 333.3 [M+H] + .

[0446] Step 5) Synthesis of tert-butyl 6'-((1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid

[0447] To a solution of 1-methyl-3-(4-((triisopropylsilyl)ethynyl)-1H-pyrazol-1-yl)cyclobut-1-ol (200 mg, 0.60 mmol) and tert-butyl 6'-iodo-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid tert-butyl ester (0.25 g, 0.60 mmol) in THF (15 mL), cuprous iodide (0.023 g, 0.12 mmol), DIPEA (0.23 g, 1.80 mmol), TBAF (0.31 g, 1.2 mmol), and palladium dichloride bis(triphenylphosphine) (0.042 g, 0.060 mmol) were added, and the reaction was carried out at room temperature under nitrogen protection. After the reaction was completed, the system was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE / EtOAc (V / V) = 100 / 30) to obtain the target product (130 mg, yield 46.73%) as a pale yellow liquid. LC-MS (ESI, pos.ion) m / z: 463.2 [M+H] + .

[0448] Step 6) Synthesis of tert-butyl 6'-((1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid

[0449] TFA (0.97 mL, 13 mmol) was added to 5 mL of DCM containing 120 mg (0.26 mmol) of 6'-((1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid tert-butyl ester (DCM) and reacted at room temperature. After the reaction was complete, 100 mL of ethyl acetate was added to the reaction solution, and the mixture was washed four times with 50 mL of saturated sodium bicarbonate solution. The organic layers were combined and concentrated under reduced pressure. The residue was purified by column chromatography (DCM / MeOH (V / V) = 0–3%) to give a colorless viscous substance (50 mg, yield 53.18%). LC-MS (ESI, pos.ion) m / z: 363.0 [M+H] + .

[0450] Step 7) Synthesis of 1-(4-amino-7-fluoro-1,3-dihydro[3,4-c]quinoline-8-carbonyl)-6'-(1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0451] DIPEA (0.066 g, 0.51 mmol) was added to 5 mL of DCM containing 0.055 g (0.22 mmol) of 4-amino-7-fluoro-1H,3H-furano[3,4-c]quinoline-8-carboxylic acid and HATU (0.084 g, 0.22 mmol), and the mixture was stirred at room temperature for 30 minutes. Then, 90 mg (0.17 mmol) of 6'-((1-(3-hydroxy-3-methylcyclobutyl)-1H-pyrazol-4-yl)ethynyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-1-carboxylic acid tert-butyl ester was added, and the mixture was stirred at room temperature. After the reaction was complete, the reaction mixture was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (DCM / MeOH (V / V) = 100 / 5) to give the target product (45 mg, yield 43.23%) as a white solid. LC-MS(ESI,pos.ion)m / z:592.9[M+H] + .

[0452] 1H NMR (599MHz, DMSO-d6) δ8.18(s,1H),7.79(d,J=7.7Hz,1H),7.74(s,1H),7.69(d,J=7.6Hz, 1H),7.31(d,J=12.5Hz,1H),7.26(dd,J=7.6,1.4Hz,1H),7.13(d,J=1.4Hz,1H),6.93(s,2H) ,5.37(q,J=3.9Hz,2H),5.23(s,1H),5.00(t,J=3.5Hz,2H),4.55–4.50(m,1H),4.32(d,J=10 .0Hz,1H),4.30(s,2H),4.24(d,J=9.9Hz,1H),3.15(s,3H),2.49–2.46(m,4H),1.32(s,3H).

[0453] Example 43: 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-((1-(1-methylazacyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0454] Step 1: Synthesis of 6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0455] To a 50 mL single-necked flask, tert-butyl 6'-iodo-1'-methyl-2'-oxo-1',2'-dihydrospiro[azacyclobutane-3,3'-indole]-1-carboxylic acid ester (1.0 g, 2.41 mmol), dichloromethane (10 mL), and trifluoroacetic acid (5.50 g, 48.2 mmol) were added sequentially, and the reaction was carried out at room temperature. After the reaction was completed, the solvent and excess trifluoroacetic acid were removed by concentration under reduced pressure. The pH was adjusted to 8 with 1 M potassium carbonate aqueous solution. The residue was purified by silica gel column chromatography (eluting solvent: DCM / MeOH (v / v) = 10 / 1) to give 701.0 mg of yellow solid product, yield 92.44%. LC-MS (ESI, pos.ion) m / z: 315.0 [M+H] + .

[0456] Step 2: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0457] 4-Amino-7-fluoro-1H,3H-furan[3,4-c]quinoline-8-carboxylic acid (750.84 mg, 3.02 mmol), N,N,N',N'-tetramethyl-O-(7-azabenzotriazol-1-yl)hexafluorophosphate urea (1794.31 mg, 4.72 mmol), dichloromethane (13 mL), acetonitrile (13 mL), N,N-diisopropylethylamine (1563.80 mg, 12.1 mmol), and 6'-iodo-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (760 mg, 2.42 mmol) were added sequentially to a 100 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was complete, the pH was adjusted to 7-8 with 1M ammonium chloride aqueous solution to quench the reaction. The organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (200 mL) and then extracted with ethyl acetate (30 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 10 / 1) to give 1.25 g of white solid product, yield 95.09%. LC-MS (ESI, pos.ion) m / z: 545.0 [M+H] + .

[0458] Step 3: Synthesis of tert-butyl-3-hydroxyazacyclobutane-1-carboxylic acid ester

[0459] Azacyclobutane-3-ol (1.0 g, 13.68 mmol), dichloromethane (40 mL), triethylamine (3.46 g, 34.2 mmol), and di-tert-butyl dicarbonate (3.73 g, 17.1 mmol) were added sequentially to a 100 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was completed, the pH was adjusted to 7-8 with 1 M ammonium chloride aqueous solution to quench the reaction. The solvent was removed by concentration under reduced pressure, and the residue was purified by silica gel column chromatography (eluting solvent: PE / EtOAc (v / v) = 3 / 1) to give 1.85 g of yellow oily product, yield 78.07%. LC-MS (ESI, pos.ion) m / z: 118.0 [M-56+H] + .

[0460] Step 4: Synthesis of tert-butyl-3-(p-toluenesulfonyloxy)azacyclobutane-1-carboxylic acid ester

[0461] To a 250 mL single-necked flask, tert-butyl-3-hydroxyazacyclobutane-1-carboxylic acid ester (2.37 g, 13.68 mmol), dichloromethane (50 mL), acetonitrile (50 mL), triethylamine (3.46 g, 34.2 mmol), p-toluenesulfonyl chloride (3.26 g, 17.1 mmol), and 4-dimethylaminopyridine (0.42 g, 3.42 mmol) were added sequentially, and the mixture was reacted at 50 °C under nitrogen atmosphere. After the reaction was complete, the pH was adjusted to 7 with 1M ammonium chloride aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (300 mL), and then extracted with dichloromethane (50 mL × 3). The organic phases were combined, washed with saturated brine (150 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluting agent: PE / EtOAc (v / v) = 6 / 1) to give 2.91 g of a colorless oily product, with a yield of 64.96%. LC-MS (ESI, pos.ion) m / z: 272.0 [M-56+H] + .

[0462] Step 5: Synthesis of tert-butyl 3-(4-iodo-1H-pyrazole-1-yl)azacyclobutane-1-carboxylic acid ester

[0463] 4-Iodopyrazole (100.0 mg, 0.52 mmol), tert-butyl-3-(p-toluenesulfonyloxy)azacyclobutane-1-carboxylic acid ester (166.84 mg, 0.51 mmol), cesium carbonate (423.57 mg, 1.3 mmol), and N,N-dimethylformamide (5 mL) were added sequentially to a 25 mL single-necked flask, and the reaction was carried out at 80 °C. After the reaction was completed, the resulting mixture was diluted with water (100 mL), and then extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluting agent: PE / EtOAc (v / v) = 6 / 1) to give 118.0 mg of a colorless oily product, with a yield of 65.55%. LC-MS(ESI,pos.ion)m / z:293.9[M-56+H] + .

[0464] Step 6: Synthesis of tert-butyl 3-(4-((trimethylsilyl)ethynyl)-1H-pyrazole-1-yl)azacyclobutane-1-carboxylic acid ester

[0465] To a 50 mL single-necked flask, tert-butyl 3-(4-iodo-1H-pyrazol-1-yl)azacyclobutane-1-carboxylic acid ester (1.25 g, 3.58 mmol), cuprous iodide (0.068 g, 0.36 mmol), bis(triphenylphosphine) palladium dichloride (0.25 g, 0.36 mmol), tetrahydrofuran (12.5 mL), trimethylsilylacetylene (0.44 g, 4.47 mmol), and triethylamine (0.91 g, 8.95 mmol) were added sequentially, and the reaction was carried out at room temperature under nitrogen atmosphere. After the reaction was complete, the pH was adjusted to 6-7 with 1M ammonium chloride aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (100 mL), and then extracted with dichloromethane (20 mL × 3). The organic phases were combined, washed with saturated brine (60 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluting solvent: PE / EtOAc (v / v) = 6 / 1) to give 808.5 mg of a pale yellow solid product, with a yield of 70.69%. LC-MS (ESI, pos.ion) m / z: 264.2 [M-56+H] + .

[0466] Step 7: Synthesis of tert-butyl 3-(4-((1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-6'-yl)ethynyl)-1H-pyrazole-1-yl)azacyclobutane-1-carboxylic acid ester

[0467] Add 250 mg (0.46 mmol) of 1-(4-amino-7-fluoro-1H,3H-furan[3,4-c]quinoline-8-carbonyl)-6'-iodo-1'-methyl-1',2'-dihydrospiro[azacyclobutane-3,3'-indole]-2'-one, tert-butyl-3-(4-(2-(trimethylsilyl)ethynyl)-1H-pyrazol-1-yl)azacyclobutane-1- Carboxylic acid ester (220.43 mg, 0.69 mmol), cuprous iodide (8.76 mg, 0.046 mmol), palladium dichloride of bis(triphenylphosphine) (32.29 mg, 0.046 mmol), N,N-dimethylformamide (15 mL), triethylamine (116.37 mg, 1.15 mmol) and tetrabutylammonium fluoride (240.54 mg, 0.92 mmol) were reacted at room temperature under nitrogen atmosphere. After the reaction was complete, the pH was adjusted to 6-7 with 1M ammonium chloride aqueous solution, the organic solvent was removed by concentration under reduced pressure, the resulting mixture was diluted with water (100 mL), and then extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: DCM / MT (v / v) = 15 / 1) to give 258.5 mg of yellow solid product, yield 84.80%. LC-MS (ESI, pos.ion) m / z: 664.1 [M+H] + .

[0468] Step 8: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-(azacyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one

[0469] To a 50 mL single-necked flask, tert-butyl 3-(4-((1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-1'-methyl-2'-oxospiro[azacyclobutane-3,3'-indoline]-6'-yl)ethynyl)-1H-pyrazole-1-yl)azacyclobutane-1-carboxylic acid ester (100 mg, 0.15 mmol), dichloromethane (10 mL), and trifluoroacetic acid (342.06 mg, 3 mmol) were added sequentially, and the reaction was carried out at room temperature. After the reaction was completed, the solvent and excess trifluoroacetic acid were removed by concentration under reduced pressure. The pH was adjusted to 8 with 1 M potassium carbonate aqueous solution. The residue was purified by silica gel column chromatography (eluting agent: DCM / MeOH (v / v) = 8 / 1) to give 75.0 mg of a pale yellow solid product, with a yield of 88.32%. LC-MS(ESI,pos.ion)m / z:564.1[M+H] + .

[0470] Step 9: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-1'-methyl-6'-((1-(1-methylazacyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0471] To a 25 mL single-necked flask, 1-(4-amino-7-fluoro-1,3-dihydrofuran[3,4-c]quinoline-8-carbonyl)-6'-((1-(azacyclobutane-3-yl)-1H-pyrazol-4-yl)ethynyl)-1'-methylspiro[azacyclobutane-3,3'-indoline]-2'-one (25.0 mg, 0.044 mmol), aqueous formaldehyde solution (10.71 mg, 0.13 mmol, 37%), dichloromethane (3 mL), methanol (3 mL), triethylamine (6.68 mg, 0.066 mmol), and acetic acid (3.96 mg, 0.066 mmol) were added sequentially. After 3 hours, sodium cyanoborohydride (2.76 mg, 0.044 mmol) was added, and the reaction was continued at room temperature. After the reaction was complete, the pH was adjusted to 7-8 with 1M potassium carbonate aqueous solution, and the organic solvent was removed by concentration under reduced pressure. The resulting mixture was diluted with water (100 mL), and then extracted with ethyl acetate (20 mL × 3). The organic phases were combined, washed with saturated brine (100 mL × 1), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 8 / 1) to give 8.0 mg of a pale yellow solid product, with a yield of 31.22%. LC-MS (ESI, pos.ion) m / z: 578.1 [M+H] + .

[0472] 1 H NMR(400MHz,DMSO-d6)δ8.28(s,1H),7.86(s,1H),7.81–7.66(m,2H),7.36–7.22(m,2H),7.13(s,1H),6.92(s,2H),5.36(s ,2H),5.23–5.08(m,1H),4.99(s,2H),4.43–4.18(m,4H),4.17–3.98(m,2H),3.93–3.74(m,2H),3.14(s,3H),2.61(s,3H).

[0473] Example 44: 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-(methyl-d3)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0474] Step 1: Synthesis of tert-butyl 6'-iodo-1'-(methyl-d3)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid

[0475] Add 2.0 g (5.0 mmol) of 6'-iodo-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester, 0.26 g (6.5 mmol) of deuterated iodomethane, and 20 mL of tetrahydrofuran to a 100 mL double-necked flask. Protect the flask with nitrogen and cool it to 0 °C. After stirring for 0.5 h, add sodium hydride (0.94 g, 6.5 mmol) and continue stirring for 10 min. Continue the reaction at room temperature. After the reaction was complete, the system was poured into water (100 mL), and then extracted with ethyl acetate (50 mL × 2 times). The organic layers were combined, dried over anhydrous sodium sulfate, and concentrated under reduced pressure to remove the solvent. The residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 3 / 1) to give 2.0 g of white solid product, yield 95.9%. LC-MS (ESI, pos.ion) m / z: 418.2 [M+H] + .

[0476] Step 2: Synthesis of 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-(methyl-d3)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester

[0477] To a 100 mL single-necked flask, tert-butyl 6'-iodo-1'-(methyl-d3)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid was added sequentially: tert-butyl 6'-iodo-1'-(methyl-d3)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid (tert-butyl 6'-triphenylphosphine dichloride) (67 mg, 0.096 mmol), tetrahydrofuran (30 mL), triethylamine (0.97 g, 9.58 mmol), and tetrabutylammonium fluoride (1.50 g, 5.75 mmol). Under nitrogen protection, a tetrahydrofuran (10 mL) solution of 1-cyclopropyl-4-((trimethylsilyl)ethynyl)-1H-pyrazole (1.08 g, 5.27 mmol) was added dropwise, and the reaction was allowed to proceed at room temperature for 8 h. After the reaction was complete, 500 mL of ethyl acetate was added to the reaction solution, followed by washing with saturated brine (30 mL × 3 times). The organic layer was dried over anhydrous sodium sulfate, concentrated under reduced pressure to remove the solvent, and the residue was purified by silica gel column chromatography (eluent: PE / EtOAc (v / v) = 15 / 1) to give 0.31 g of a yellow solid product, with a yield of 15.34%. LC-MS (ESI, pos.ion) m / z: 422.2 [M+H] + .

[0478] Step 3: Synthesis of 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-(methyl-d3)spiro[azacyclobutane-3,3'-dihydroindole]-2'-one

[0479] 6'-(1-cyclopropyl-1H-pyrazole-4-ylethynyl)-1'-(methyl-d3)-2'-oxospiro[azacyclobutane-3,3'-dihydroindole]-1-carboxylic acid tert-butyl ester (0.31 g, 0.74 mmol), dichloromethane (5 mL), and trifluoroacetic acid (0.71 mg, 6.25 mmol) were added sequentially to a 50 mL single-necked flask, and the reaction was carried out at room temperature. After the reaction was completed, the solvent, a large amount of trifluoroacetic acid, was removed by concentration under reduced pressure. The pH was then adjusted to 7-8 with 1 M potassium carbonate aqueous solution, and the resulting mixture was diluted with water (50 mL). The mixture was then extracted with ethyl acetate (10 mL × 3). The organic phases were combined and washed with saturated brine (30 mL × 1). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to remove the solvent, yielding 0.24 g of crude product, with a yield of 97.3%. LC-MS (ESI, pos.ion) m / z: 322.2 [M+H] + .

[0480] Step 4: Synthesis of 1-(4-amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-formyl)-6'-[(1-cyclopropyl-1H-pyrazol-4-yl)ethynyl]-1'-(methyl-d3)spiro[azacyclobutane-3,3'-indoline]-2'-one

[0481] 4-Amino-7-fluoro-1,3-dihydrofurano[3,4-c]quinoline-8-carboxylic acid (0.18 g, 0.73 mmol), HATU (0.33 mg, 0.88 mmol), DMF (10 mL), and N,N-diisopropylethylamine (0.28 g, 2.19 mmol) were added sequentially to a 10 mL single-necked flask. After reacting at room temperature for 0.5 hours, 6'-(1-cyclopropyl-1H-pyrazol-4-ylethynyl)-1'-(methyl-d3)spiro[azacyclobutane-3,3'-dihydroindole]-2'-one (0.24 g, 0.75 mmol) was added, and the reaction was continued at room temperature. After the reaction was complete, ethyl acetate (200 mL) was added to the system, and the mixture was washed with saturated brine (30 mL × 3 times). The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed by concentration under reduced pressure. The residue was purified by silica gel column chromatography (eluent: DCM / MeOH (v / v) = 24 / 1) to give 0.28 g of a white solid product, yield 70%. LC-MS (ESI, pos.ion) m / z: 552.2 [M+H] + .

[0482] 1H NMR (400MHz, CDCl3) δ7.84 (d, J = 7.4Hz, 1H), 7.67 (s, 1H), 7.63 (s, 1H), 7.52 (d,J=7.6Hz,1H),7.39(d,J=11.9Hz,1H),7.29(d,J=7.8Hz,1H),6.98(s,1H ),5.45(t,J=3.3Hz,2H),5.15(t,J=3.1Hz,2H),4.92(s,2H),4.58(dd,J=61 .6,9.1Hz,2H),4.35(d,J=9.3Hz,2H),3.61–3.58(m,1H),1.16–1.03(m,4H).

[0483] Biological activity test cases

[0484] Test Example 1: Cell proliferation inhibition

[0485] 1-1, Experiment A

[0486] 1.1 Experimental Materials

[0487] HCT116-WT cells were purchased from the ATCC Biostandard Resource Center in the United States.

[0488] HCT116-MTAP(- / -) cells are MTAP knockout HCT116 cells, independently constructed by Kanglong Chemical (Beijing) New Drug Technology Co., Ltd. based on HCT116-WT cells.

[0489] MCCOYS 5A culture medium is from Gibco.

[0490] 1.2 Experimental Procedure

[0491] 1) Cell resuscitation and culture: HCT116-WT cells and HCT116-MTAP(- / -) cells were resuscitated and cultured in MCCOYS 5A medium containing a mixture of 10% FBS and 1% penicillin and streptomycin in a saturated humidity incubator at 37°C and 5% CO2.

[0492] 2) Cell plating: After passage 2-3 times, when the cells enter the exponential growth phase with good growth, collect the cells (the cell viability should be above 90%) and add 150 cells / 40μL to each well of a 384-well plate.

[0493] 3) Compound preparation and sample loading: Dissolve the compound in DMSO to a stock solution with a concentration of 10 mM, and prepare the corresponding drug dilution: start at a total concentration of 10 μM, and perform 3-fold serial dilutions to set 10 concentration points; additionally, set up control wells containing culture medium and control wells containing 0.1% DMSO solvent. Transfer 40 nmol of the prepared drug dilution to the above-mentioned 384-well plate containing cells, with 2 replicates, and incubate in a 37°C, 5% CO2 saturated humidity incubator for 10 days.

[0494] 4) Plate reading test: Add 40nl of CTG to each well ( The luminescence cell viability assay kit was incubated in the dark for 30 minutes, and the luminescence signal value was detected on a plate reader.

[0495] 1.3 Data Processing

[0496] Inhibition rate % = 100 - (Emission signal value of drug administration wells – Average emission signal value of culture medium wells) / (Average emission signal value of solvent control wells – Average emission signal value of culture medium wells) * 100

[0497] IC 50 Value calculation method: IC is obtained by nonlinear fitting formula using Graph Pad Prism 8.0 software. 50 The value is calculated using the following formula:

[0498] Y=Bottom+(Top-Bottom) / (1+10^((LogIC 50 -X)×HillSlope))

[0499] Y: Inhibition rate; X: Log value of compound concentration; IC50 50 : Half-maximal inhibitory concentration.

[0500] 1.4 Experimental Results

[0501] Table 1-1 Inhibitory activity of compounds on the proliferation of HCT116-MTAP(- / -) cells and HCT116-WT cells Note: A≤10nM, 10nM<B≤100nM,C> 100nM.

[0502] It is evident that the compounds of this invention exhibit good inhibitory activity against the proliferation of HCT116 MTAP(- / -) cells.

[0503] Test Example 2: Stability in Liver Microsomes

[0504] 2.1 Test Instruments and Parameters

[0505] 1) The LC / MS / MS system used for analysis included a Shimadzu LC-40BXR series vacuum degassing valve, a binary injection pump, an autosampler, a column oven, and an AB QTRAP5500+ mass spectrometer with an electrospray ionization (ESI) source. Quantitative analysis was performed in MRM mode, and the mass spectrometry parameters are shown in Table 2.

[0506] Table 2 Mass Spectrometry Parameters

[0507] 2) An Agilent Polaris 5C18-A 30*2.0mm column was used for analysis. The analytical conditions were: H2O + 2mM ammonium formate + 0.1% FA (mobile phase A) and MeOH + 2mM ammonium formate + 0.1% FA (mobile phase B). The flow rate was 0.500 mL / min. The mobile phase gradient is shown in Table 3.

[0508] Table 3 Mobile Phase Gradient

[0509] 2.2 Preparation of Reagents and Solutions

[0510] Human liver microsomes were purchased from Corning (lot number: 1151001).

[0511] Verapamil was purchased from Aladdin. PRO was propranolol, and compound a was Ritapiram, prepared according to WO2016037591A1. The structure of compound a is as follows:

[0512] 1) PRO & compound a stock solution (500 μg / mL): Take 250 μL of propranolol (4 mg / mL) and 500 μL of compound a (2 mg / mL) as internal standard stock solution, add them to 1250 μL of DMSO and mix well.

[0513] 2) Preparation of stock solutions: Weigh a certain amount of the test compound (i.e., the compound of this invention) and verapamil and prepare stock solutions with a concentration of 10 mM using DMSO, and store them in a refrigerator at -20℃; prepare a stock solution of deuterated internal standard with a concentration of 1 mg / mL using DMSO, store it in a refrigerator at -20℃ for later use, and then dilute it with acetonitrile to a certain concentration before analysis.

[0514] 3) Preparation of 0.1M potassium dihydrogen phosphate buffer solution (pH=7.4): Weigh a certain amount of potassium dihydrogen phosphate and dissolve it in ultrapure water by sonication to a concentration of 0.1M; weigh a certain amount of dipotassium hydrogen phosphate and dissolve it in ultrapure water by sonication to a concentration of 0.1M; slowly add the 0.1M potassium dihydrogen phosphate solution to the 0.1M dipotassium hydrogen phosphate solution, and stop when the pH reaches 7.4.

[0515] 4) Preparation of the compound and verapamil working solution:

[0516] 100 μM drug delivery solution: Add 5 μL of 10 mM stock solution to 495 μL of acetonitrile:water (1:1);

[0517] 30μM drug delivery solution: Add 60μL of 100μM drug delivery solution to 140μL of 0.1M potassium phosphate buffer.

[0518] 1.5 μM Dosage Solution: Add 30 μL of 30 μM dosage solution and 23.00 μL (20 mg / mL) of liver microsomes to 547.00 μL of 0.1 M potassium phosphate buffer, one solution per species.

[0519] 5) Preparation of NADPH solution: Weigh a certain amount of NADPH test sample (purchased from Bangtai Biotechnology (Shenzhen) Co., Ltd., batch number: BT04T122M003) and prepare a 6mM NADPH solution with buffer solution.

[0520] 6) Preparation of internal standard working solution: Take 180 μL of PRO & compound a stock solution (500 μg / mL) and 0.5 L of ACN, add 0.5 L of MeOH solution, and mix well.

[0521] 2.3 Experimental Procedure

[0522] 1) Preparation of working solutions: Working solution 01: Take 5 μL of the test compound or verapamil stock solution (10 mM) and add it to 495 μL of 50% ACN / H2O; Working solution 02: Take 60 μL of the test compound or verapamil working solution (100 μM) and add it to 140 μL of 0.1 M potassium phosphate buffer (hereinafter referred to as buffer).

[0523] 2) Take a 96-well plate, name it according to the required testing time, and divide the plate positions accordingly;

[0524] 3) Take 18.8 μL of liver microsomes (20 mg / mL) and add it to 456.2 μL of buffer. Pre-incubate the liver microsome solution and working solution O2 at 37 °C for about 10 min.

[0525] 4) Add 25 μL of the test compound or verapamil working solution O2 to the liver microsome solution, mix well, take out 30 μL of the mixed solution, add 150 μL of MeOH:ACN (1:1) stop solution containing internal standard, and then add 15 μL of NADPH solution (6 mM) and mix well to obtain the T0 sample.

[0526] 5) Take another 30 μL of the above mixed solution and transfer it to the wells of the 96-well plate at the corresponding time points. Add 15 μL of buffer to the NCF90 well and add 15 μL of NADPH solution (6 mM) to the other time points. The final reaction system contains 0.5 mg / mL liver microsomal protein and 2 mM NADPH.

[0527] 6) Incubate for time and add 150 μL of MeOH:ACN (1:1) stop solution containing internal standard at 15 min, 30 min, 60 min and 90 min respectively;

[0528] 7) Pretreatment: After centrifugation at 4000 rpm for 5 min, take 75 ± 75 μL of the supernatant and add it to 100 μL of ultrapure water. Mix well and perform LC-MS / MS analysis. Some compounds were analyzed using a cassette.

[0529] 2.4 Data Processing

[0530] Peak areas were determined based on the extracted ion chromatograms. The slope value k was determined through linear regression of the natural logarithm of the remaining percentage of parent drug against the incubation time curve. The in vitro half-life (in vitro t) was determined based on the slope value. 1 / 2 ):

[0531] in vitro t 1 / 2 =-(0.693 / k)

[0532] The following equation (average value of duplicate well measurements) is used to calculate the in vitro t 1 / 2 (min) is converted to in vitro intrinsic clearance rate (in vitro CLint, in μL / min / mg protein):

[0533] The equations were used to calculate CLint (mL / min / kg), predict liver CLHep (mL / min / kg), and liver extraction rate (ER): (ref.: Naritomi Y, Terashita S, Kimura S, Suzuki A, Kagayama A, Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metabolism and Disposition 2001, 29:1316-1324.).

[0534] Table 4. Experimental results on the stability of the compounds of this invention in liver microparticles.

[0535] The results show that the compounds of this invention have good metabolic stability in human liver microparticles.

[0536] Test Example 3: Pharmacokinetic Evaluation

[0537] 3.1 Experimental Materials

[0538] Male Balb / c mouse mice were purchased from Hunan Slack, and male cynomolgus monkeys were purchased from Guangzhou Huazhen Biotechnology Co., Ltd.

[0539] Preparation of compound solutions: The test compound was prepared into a solution using 10% dimethyl sulfoxide (purchased from Beijing Innocare Technology Co., Ltd.), 10% Kolliphor HS15 (a powerful nonionic solubilizer and emulsifier, purchased from BASFSE) and 80% physiological saline for oral or intravenous administration.

[0540] 3.2 Experimental Procedure

[0541] Male Balb / c mice weighing 25-30g were randomly divided into two groups. One group was given the test compound intravenously at a dose of 2.0 mg / kg, and the other group was given the test compound orally at a dose of 5 mg / kg. Blood samples were collected at time points of 0.083, 0.25, 0.5, 1, 2, 5, 7 and 24 hours after administration.

[0542] Male cynomolgus monkeys weighing 6-10 kg were divided into two groups. One group was given the test compound intravenously at a dose of 0.5 mg / kg, and the other group was given the test compound orally at a dose of 2.5 mg / kg. Blood samples were collected at time points of 0.25, 0.5, 1, 2, 4, 6, 8 and 24 hours after administration, with an additional 0.083 hours after intravenous administration.

[0543] Establish a standard curve within an appropriate range based on the sample concentration, using AB SCIEX Q TRAP 5500. + A novel LC-MS / MS model was used to determine the concentration of the analyte in plasma samples in MRM mode. Pharmacokinetic parameters were calculated using a non-compartmental model.

[0544] The results show that the compound of this invention has good pharmacokinetic effects.

[0545] In the description of this specification, the references to terms such as "one embodiment," "some embodiments," "example," "specific example," or "some examples," etc., indicate that a specific feature, structure, material, or characteristic described in connection with that embodiment or example is included in at least one embodiment or example of the present invention. In this specification, the illustrative expressions of the above terms do not necessarily refer to the same embodiment or example. Furthermore, the specific features, structures, materials, or characteristics described may be combined in any suitable manner in one or more embodiments or examples. Moreover, without contradiction, those skilled in the art can combine and integrate the different embodiments or examples described in this specification, as well as the features of different embodiments or examples.

[0546] Although embodiments of the present invention have been shown and described above, it is understood that the above embodiments are exemplary and should not be construed as limiting the present invention. Those skilled in the art can make changes, modifications, substitutions and variations to the above embodiments within the scope of the present invention.

Claims

1. A compound that is a compound of formula (I) or a stereoisomer, tautomer, nitrogen oxide, solvate, metabolite, metabolic precursor, pharmaceutically acceptable salt, or prodrug of a compound of formula (I). in, R is It can be a single or double bond; L represents C. 2-6 imide or C 2-6 Ethyne group; X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl groups; X4 represents N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl groups; W represents O, S, and NR. W1 or C(R) W2 )2; R on N W1 For H, D, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Haloalkyl; 2 Rs on C W2 Whether they are the same or different, each R W2 Each is independently H, D, -CN, halogen, C 1-6 Alkyl, C 1-6 Hydroxyalkyl or C 1-6 Halogenated alkyl group, or two R groups on C W2 Together with the carbon atoms bonded to them, they form =O or =S; Ring A and ring B are each independently C 3-6 Carbocyclic rings, 3-10 membered heterocyclic rings, 5-10 membered heteroaromatic rings, or C 6-10 Aromatic rings; R 1 H, D, halogen, -CN, -NR a R b C 1-6 Alkyl, C 1-6 Alkoxy or C 1-6 Halogenated alkyl groups; Each R 2 Each is independently D, halogen, -CN, -NO2, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 alkenyl, C 2-6 alkynyl or C 1-6 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms bonded to them, they form =O or =S; Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-6 Alkyl, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic groups, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Halogenated alkyl or C 1-6 Deuterated alkyl, or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S; Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-6 Alkyl or C 1-6 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6 Carbon rings or 3-10 membered heterocyclic rings; Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-6 Alkyl or C 1-6 Halogenated alkyl groups; R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10 Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 4 Replaced; Each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl or C 6-10 Aryl, wherein the C 1-6 Alkyl, C 1-6 Heteroalkyl, C 1-6 Alkoxy, C 3-6 Cycloalkyl, 3-10 membered heterocyclic, 5-10 membered heteroaryl and C 6-10 Each aryl group can be independently and optionally bounded by 1, 2, 3 or 4 R groups. 5 The replaced; or two R atoms attached to the same carbon atom 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ; Each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 Cycloalkyl or 3-10 membered heterocyclic groups; wherein, the C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Heteroalkyl, C 3-6 The cycloalkyl or 3-10 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-6 Alkyl, C 1-6 Alkoxy, C 1-6 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ; Each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-6 Alkyl, C 3-6 cycloalkyl, C 1-6 Heteroalkyl or C 1-6 Halogenated alkyl groups; Each R p R q R s R t Independent of H, D, halogen, C 1-6 Alkyl, C 1-6 Heteroalkyl or C 1-6 Halogenated alkyl groups; The values ​​of S1 and S2 are positive integers, and the sum of S1 and S2 is 2, 3 or 4; m can be 0, 1, 2, 3, 4, 5, or 6.

2. The compound according to claim 1, wherein, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c C 1-4 Alkyl, C 1-4 Heteroalkyl, C 3-6 cycloalkyl, 3-6 membered heterocyclic, C 1-4 Halogenated alkyl or C 1-4 Deuterated alkyl; two Rs on C Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c Halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Halogenated alkyl or C 1-4 Deuterated alkyl; or two Rs on C Y1b Together with the carbon atoms bonded to them, they form =O or =S; Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a For H, D, C 1-4 Alkyl or C 1-4 Haloalkyl; 2 Rs on C Y2b Whether they are the same or different, each R Y2b Each is independently H, D, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl group, or two R groups on C Y2b Together with the carbon atoms bonded to them, they form =O, =S, and =C. 3-6 Carbon rings or 3-6 membered heterocycles; Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each is independently H, D, -CN, halogen, C 1-4 Alkyl or C 1-4 Halogenated alkyl groups.

3. The compound according to claim 2, wherein, Y1 is O, S, S(=O), S(=O)2, NR Y1a or C(R) Y1b )2, R on N Y1a For H, D, -C (=O)R c -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolidine, 2-pyrrololinyl, 3- Pyrrololinyl, pyrazolinyl, pyrazoloalkyl, imidazolinyl, imidazoalkyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyridyl, dihydropyridyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CD3, -CHD2, -CH2D, -CHDCH3, -CD2CH3, -CH2CHD2, -CH2CH2D or -CH2CD3; the two Rs on C. Y1b Whether they are the same or different, each R Y1b Each is independently H, D, -CN, -C(=O)R c , F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH 3. -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, - CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CD3, -CHD2, -CH2D, -CHDCH3, -CD2CH3, -CH2CHD2, -CH2CH2D or -CH2CD3; or two Rs on C. Y1b Together with the carbon atoms bonded to them, they form =O or =S; Y2 is O, S, S(=O), S(=O)2, NR Y2a or C(R) Y2b )2, R on N Y2a The two Rs on the C are H, D, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br; Y2b Whether they are the same or different, each R Y2b Each can independently be H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs on C. Y2b Together with the carbon atoms bonded to them, they form =O, =S, cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, ethylene oxide, azacyclobutane, oxacyclobutane, thiocyclobutane, pyrrolidine, pyrrololine, pyrazolin, pyrazolidine, imidazoline, imidazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, dioxocyclopentane, dithiocyclopentane, tetrahydropyran, dihydropyran, 2H-pyran, 4H-pyran, tetrahydrothiaran, piperidine, morpholine, thiomorpholine, piperazine, dioxane, dithiazide, or thiazide; Z1 is N or CR Z1 Z2 is N or CR Z2 Z3 is N or CR Z3 Z4 is N or CR Z4 ;R Z1 R Z2 R Z3 and R Z4 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br.

4. The compound according to any one of claims 1-3, wherein, R 3 For H, D, -S(=O)2R d -NR e R f Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl, 3-9 membered heterocyclic, 5-9 membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 4 Replaced; Each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i Halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6 membered heterocyclic, 5-6 membered heteroaryl or phenyl, wherein the C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Alkoxy, C 3-6 Cycloalkyl, 3-6-membered heterocyclic, 5-6-membered heteroaryl, and phenyl groups are each independently and optionally surrounded by 1, 2, 3, or 4 R groups. 5 The replaced; or two R atoms attached to the same carbon atom 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ; Each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m Halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 Cycloalkyl or 3-6 membered heterocyclic groups; wherein, the C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Heteroalkyl, C 3-6 The cycloalkyl or 3-6 membered heterocyclic group is independently and optionally surrounded by 1, 2, 3 or 4 D, -CN, -OH, halogen, C 1-4 Alkyl, C 1-4 Alkoxy, C 1-4 Substituents of haloalkyl groups; or two R groups attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ; Each R a R b R c R d R e R f R g R h R i R j R k R m Independent of H, D, halogen, C 1-4 Alkyl, C 3-6 cycloalkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups; Each R p R q R s R t Independent of H, D, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl or C 1-4 Halogenated alkyl groups.

5. The compound according to any one of claims 1-4, wherein, R 3 For H, D, -S(=O)2R d -NR e R f , F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH 3. -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHC H2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thioheridine, pyrrolyl, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyridyl, dihydropyridyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, furanyl Imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazinyl, 1,3,5-triazinyl, pyrazolopyridine, dihydropyrroloimidazole or phenyl, wherein -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH3, -CH2SCH3, -CH2OC H2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxaziridine, thioaziridine, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-Dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiaranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxylalkyl, dithiaalkyl, thiaoxylalkyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrroleyl, pyridinyl, pyrimidinyl, pyridazinyl, pyrazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazine, 1,3,5-triazinyl, pyrazolopyridine, dihydropyrroleimidazole, and phenyl are each independently and optionally divided by 1, 2, 3, or 4 Rs. 4 Replaced; Each R 4 Each can be independently -OH, D, -CN, or -S(=O)2R g -NR h R i , F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2 CH3, -OCH3, -OCH2CH3, -OCH(CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolyl, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiopheneyl, dihydrothiopheneyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiopheneyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, thiaalkyl, furanyl Imidazolyl, isoxazolyl, oxazolyl, pyrrolyl, pyridyl, pyrimidinyl, pyridazinyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazinyl, 1,3,5-triazinyl or phenyl, wherein -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -C H2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -OCH3, -OCH2CH3, -OCH(CH3)2, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiocyclobutyl, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolylyl, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-Dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiaranyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxylalkyl, dithiaalkyl, thiaoxylalkyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrroleyl, pyridinyl, pyrimidinyl, pyridazinyl, thiazolyl, thiazolyl, tetrazolyl, triazolyl, thiophene, pyrazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiodiazolyl, pyrazine, 1,3,5-triazinyl, and phenyl are each independently and optionally surrounded by 1, 2, 3, or 4 Rs. 5 The replaced; or two R atoms attached to the same carbon atom 4 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. p R q ; Each R 5 Each can be independently represented as D, -OH, -CN, or -S(=O)2R. j -NR k R m , F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH 2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -C H2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thioheridine, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolidine, imidazolinyl, imidazolinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl or thiaalkyl;Among them, the -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2C H2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, ethylene oxide, aziridine, oxacyclobutyl, thiohexacyclobutyl, pyrrolidine, 2-pyrrololinyl, 3-pyrrololinyl, pyrazolinyl, pyrazolylalkyl, imidazolinyl, imidazolinyl Alzolyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, 1,3-dioxocyclopentyl, dithiocyclopentyl, tetrahydropyranyl, dihydropyranyl, 2H-pyranyl, 4H-pyranyl, tetrahydrothiophenyl, piperidinyl, morpholinyl, thiomorpholinyl, piperazine, dioxyl, dithiaalkyl, and thiaalkyl are each independently and optionally surrounded by 1, 2, 3, or 4 D, -CN, -OH, F, Cl, Br, I, -CH3, -CH2CH3, - The substituents are (CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs attached to the same carbon atom. 5 Together with the carbon atoms bonded to them, they form =O, =S, or =CR. s R t ; Each R a R b R c R d R e R f R g R h R i R j R k R m Independently, it can be H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; Each R p R q R s R t Independently H, D, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH 2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH2NHCH2CH3, -OCH2CH2NHCH2CH3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, or -CH2Br.

6. The compound according to any one of claims 1-5, wherein, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Heteroalkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups; X4 represents N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl groups; W represents O, S, and NR. W1 or C(R) W2 )2; R on N W1 For H, D, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Haloalkyl; 2 Rs on C W2 Whether they are the same or different, each R W2 Each is independently H, D, -CN, halogen, C 1-4 Alkyl, C 1-4 Hydroxyalkyl or C 1-4 Halogenated alkyl group, or two R groups on C W2 Together with the carbon atoms they are attached to, they form =O or =S.

7. The compound according to any one of claims 1-6, wherein, X1 is N or CR X1 X2 is N or CR X2 X3 is N or CR X3 X8 is N or CR X8 ;R X1 R X2 R X3 and R X8 Each of these can be independently represented as H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OCH3, -CH2SCH3, -CH2OCH2CH3, -CH2CH2OCH3, -CH2SCH2CH3, -CH2CH2SCH3, -CH2NHCH2CH3, -CH2CH2NHCH3, -CH2OCH2CH2NHCH3, -CH2CH 2NHCH2CH3, -OCH2CH2NHCH2CH3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH 2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; X4 represents N, C, or CR. X4 X5 is N, C or CR X5 X6 is N, C or CR X6 X7 is N, C or CR X7 ;R X4 R X5 R X6 and R X7 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; W represents O, S, and NR. W1 or C(R) W2 )2; R on N W1 For H, D, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -C 2 R on C W2 Whether they are the same or different, each R W2 Each can be independently H, D, -CN, F, Cl, Br, I, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CH2OH, -CH2CH2OH, -CH(OH)CH3, -CH(OH)CH2OH, -CH2CH2CH2OH, -CH2CH2CH2CH2OH, -CH2CH2OH, -CH2CH(OH)CH2CH2OH, -CH2CH(OH)CH2CH(CH3)OH, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; or two Rs on C. W2 Together with the carbon atoms they are attached to, they form =O or =S.

8. The compound according to any one of claims 1-7, wherein, Ring A and ring B are each independently C 3-6 Carbon rings, 3-6 membered heterocycles, 5-6 membered heteroaromatic rings, or benzene rings; R 1 H, D, halogen, -CN, -NR a R b C 1-4 Alkyl, C 1-4 Alkoxy or C 1-4 Halogenated alkyl groups; R 2 Each is independently D, halogen, -CN, -NO2, C 1-4 Alkyl, C 1-4 Haloalkyl, C 2-4 alkenyl, C 2-4 alkynyl or C 1-4 alkoxy group, or two R atoms attached to the same carbon atom 2 Together with the carbon atoms bonded to them, they form =O or =S; Optionally, ring A and ring B are each independently cyclopropane, cyclobutane, cyclopentane, cyclohexane, cyclobutene, cyclopentene, cyclopentadiene, cyclohexene, cyclohexadiene, benzene ring, furan, imidazole, isoxazole, oxazole, pyrrole, pyridine, pyrimidine, pyridazine, thiazole, tetrazolium, triazole, thiophene, pyrazole, isothiazole, oxadiazole, 1,2,3-triazole, thiodiazole, pyrazine, 1,3,5-triazine, 1,2,4-triazine Oxazine, ethylene oxide, azacyclobutane, oxacyclobutane, thiohexacyclobutane, pyrrolidine, pyrrololine, pyrazoline, pyrazolidine, imidazoline, imidazoline, tetrahydrofuran, dihydrofuran, tetrahydrothiophene, dihydrothiophene, dioxacyclopentane, dithiohexacyclopentane, tetrahydropyran, dihydropyran, 2H-pyran, 4H-pyran, tetrahydrothiaran, piperidine, morpholine, thiomorpholine, piperazine, dioxane, dithiazide, or thiazide; R 1 is H, D, F, Cl, Br, I, -CN, -NR a R b , -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -OCH3, -OCH2CH3, -OCH(CH3)2, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2 or -CH2Br; R 2 Each of these can be independently represented as D, F, Cl, Br, I, -CN, -NO2, -CH3, -CH2CH3, -(CH2)2CH3, -CH(CH3)2, -(CH2)3CH3, -CH2CH(CH3)2, -C(CH3)3, -CF3, -CHF2, -CH2F, -CCl3, -CHCl2, -CH2Cl, -CBr3, -CHBr2, -CH2Br, -CH=CH2, -CH2CH=CH2, -CH=CH-CH3, -C≡CH, -CH2C≡CH, -C≡C-CH3, -OCH3, -OCH2CH3, or -OCH(CH3)2, or two R atoms attached to the same carbon atom. 2 Together with the carbon atoms they are attached to, they form =O or =S.

9. The compound according to any one of claims 1-8, wherein, L is C 2-4 imide or C 2-4 Alynyl group; optionally, L is -CH=CH-, -CH2CH=CH-, -CH2CH=CHCH2-, -CH2CH2CH=CH-, -C≡C-, -CH2C≡C-, -CH2CH2C≡C- or -CH2C≡CCH2-.

10. The compound according to any one of claims 1-9, wherein it is a compound represented by formula (II-1) or (II-2), or a stereoisomer, geometric isomer, tautomer, nitride, hydrate, solvate, metabolite, metabolic precursor, pharmaceutically acceptable salt, or prodrug of the compound represented by formula (II-1) or (II-2). in, L, R, R 3 R Y1a Each has the definition as described in any one of claims 1-9.

11. The compound according to any one of claims 1-10, wherein, R is selected from any of the following structures: Among them, R X1 R X2 R X3 R X8 R 1 R 2 Each of m has the definition as described in any one of claims 1-10.

12. The compound according to any one of claims 1-11, wherein it is a structure or a stereoisomer, tautomer, nitride, solvate, metabolite, pharmaceutically acceptable salt, or prodrug that is one of the following:

13. A pharmaceutical composition comprising the compound of any one of claims 1-12 or a stereoisomer, tautomer, nitride, solvate, metabolite, pharmaceutically acceptable salt, or prodrug; optionally, further comprising a pharmaceutically acceptable carrier.

14. Use of the compound according to any one of claims 1-12 or the pharmaceutical composition according to claim 13 in the preparation of a medicament, wherein, The aforementioned medicine is used to protect against, treat, cure, or alleviate cancer in patients.

15. The use according to claim 14, wherein, The cancers mentioned are MTAP deficiency-related cancers; optionally, the MTAP deficiency-related cancers are ovarian cancer, lung cancer, lymphoma, glioblastoma, colon cancer, melanoma, gastric cancer, bile duct cancer, hepatocellular carcinoma, breast cancer, skin cancer, bladder cancer, liver cancer, pancreatic cancer, or head and neck cancer.